










PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : C07H 21/00, C12Q 1/68 C07F 9/6561, C07H 19/04, 19/10 C07H 19/20	A2	(11) International Publication Number: WO 93/16094 (43) International Publication Date: 19 August 1993 (19.08.93)
(21) International Application Number: PCT/US93/01338 (22) International Filing Date: 12 February 1993 (12.02.93) (30) Priority data: 07/834,456 12 February 1992 (12.02.92) US (71) Applicant: CHROMAGEN, INC. [US/US]; 17085 Vio del Campo, San Diego, CA 92127 (US). (72) Inventor: CONRAD, Michael, J. ; 11336 Penanova Street, San Diego, CA 92129 (US). (74) Agents: WHITLOCK, Ted, W. et al.; Saliwanchik & Saliwanchik, 2421 N.W. 41st Street, Suite A-1, Gainesville, FL 32606 (US).		(81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: APPLICATIONS OF FLUORESCENT N-NUCLEOSIDES AND FLUORESCENT STRUCTURAL ANALOGS OF N-NUCLEOSIDES (57) Abstract <p>Structural analogs of the six non-fluorescent N-nucleosides commonly found in RNA and DNA, which are inherently fluorescent under physiological conditions, are identified and methods for their preparation provided. Such analogs may be incorporated into DNA and/or RNA oligonucleotides via either enzymatic or chemical synthesis to produce fluorescent oligonucleotides having prescribed sequences. Such analogous sequences may be identical to, or the analogous complement of, template or target DNA or RNA sequences to which the fluorescent oligonucleotides can be hybridized. Methods of preparing either RNA or DNA oligonucleotide probes of the invention, intermediates used in such methods, and methods of using the probes of the invention in oligonucleotide amplification, detection, identification, and/or hybridization assays are also provided.</p> <div style="display: flex; flex-wrap: wrap; justify-content: space-around;"> <div style="text-align: center;">  <p>FORMYCIN A</p> </div> <div style="text-align: center;">  <p>FORMYCIN B</p> </div> <div style="text-align: center;">  <p>OXOFORMYCIN B</p> </div> <div style="text-align: center;">  <p>TOYOCAMYCIN</p> </div> <div style="text-align: center;">  <p>SANGIVAMYCIN</p> </div> <div style="text-align: center;">  <p>PSEUDOURIDINE</p> </div> <div style="text-align: center;">  <p>MINIMYCIN</p> </div> <div style="text-align: center;">  <p>SHOWDOMYCIN</p> </div> <div style="text-align: center;">  <p>PYRAZOMYCIN</p> </div> </div>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LJ	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

DESCRIPTIONAPPLICATIONS OF FLUORESCENT N-NUCLEOSIDES AND
FLUORESCENT STRUCTURAL ANALOGS OF N-NUCLEOSIDESBackground of the InventionA. Field of the Invention

The present invention relates to fluorescent structural analogs of the non-fluorescent nucleosides commonly found in DNA and RNA, methods of their derivatization and subsequent use in the synthesis of fluorescent oligonucleotides, and to their new and useful applications both as fluorescent monomers and in fluorescent oligonucleotides having prescribed sequences. Additionally, it relates to applications in which fluorescent structural analogs are substituted for specific non-fluorescent nucleosides in prescribed DNA or RNA sequences and to methods of using fluorescent oligonucleotides as hybridization reagents and probes for diagnostic and therapeutic purposes and as diagnostic and therapeutic research tools.

B. General Description of the Art

The six commonly occurring N-nucleosides which predominate in the composition of DNA and RNA from all sources have the structures shown in Figure 1 wherein R_6 is H for inosine and NH_2 for guanosine, R_9 is H for uridine and CH_3 for thymidine. Furthermore, R_{12} , $R_{14} = OH$ for ribonucleotides, $R_{12} = OH$, $R_{14} = H$ for 2'-deoxy nucleotides, $R_{12} = H$, $R_{14} = OH$ for 3'-deoxy nucleotides, and R_{12} , $R_{14} = H$ in dideoxy nucleotides.

The six commonly occurring nucleotides do not absorb light at wavelengths >290 nm and are effectively non-fluorescent under physiological conditions. Derivatives of the commonly occurring N-nucleotides for a variety of synthetic, diagnostic, and therapeutic purposes are common, including substitutions on both the heterocyclic base and the furanose ring. These substitutions can be made at the loci shown in Figure 2 in which R_4 is a reactive group derivatizable with a detectable label (NH_2 , SH , $=O$, and which can include an optional linking moiety including, but not limited to, an amide, thioether, or disulfide linkage or a combination thereof with additional variable reactive groups, R_1 through R_3 , e.g., $R_1-(CH_2)_x-R_2$, or $R_1-R_2-(CH_2)_x-R_3$, where x is an integer in the range of 1 and 25 inclusive; and R_1 , R_2 , and R_3 can be H, OH, alkyl, acyl, amide, thioether, or disulfide); R_5 is H or part of an etheno linkage with R_4 ; R_6 is H, NH_2 , SH , or $=O$; R_9 is hydrogen, methyl, bromine, fluorine, or iodine, or an alkyl or aromatic substituent, or an optional linking moiety including an amide, thioether, or disulfide linkage or a combination thereof such as $R_1-(CH_2)_x-R_2$, or $R_1-R_2-(CH_2)_x-R_3$, where x is an integer in the range of 1 and 25 inclusive; R_{10} is hydrogen, or an acid-sensitive base stable blocking group, or a phosphorous derivative, $R_{11}=R_{12}=H$; R_{12} is hydrogen, OH, or a

phosphorous derivative; R_{14} is H, OH, or OR_3 where R_3 is a protecting group or additional fluorophore. The letters N and C in the N-nucleosides and C-nucleosides designate the atom at which the glycosidic covalent bond connects the sugar and the heterocyclic base. In the cases of the commonly occurring nucleosides, the bases are either adenine, guanine, cytosine, inosine, uracil, or thymine. The bases are attached to a furanose sugar, a general structure of which is shown in Figure 3. The sugar substituents for the fluorescent analogs share the same numbering system for all R groups, but the numbering system for some of the heterocycle analogs may differ.

I. Known Methods of Labeling Nucleotides

Nucleotide sequences are commonly utilized in a variety of applications including diagnostic and therapeutic probes which hybridize target DNA and RNA and amplification of target sequences. It is often necessary, or useful, to label nucleotide sequences.

A. Labeling of oligonucleotide probes with radioisotopes. Hybridization of specific DNA or RNA sequences typically involves annealing oligonucleotides of lengths which range from as little as 5 bases to more than 10,000 bases (10 kb). The majority of oligonucleotide probes currently in research use are radioactively labeled; however, because of (a) the short half lives of the isotopes in common usage, (b) the safety requirements, and (c) the costs of handling and disposal of radioactive probes, convenient and sensitive non-isotopic methods of detection are required for hybridization diagnostic methods to achieve widespread acceptance and application.

B. Non-isotopic methods of labeling oligonucleotide probes. In general, all of the non-isotopic methods of detecting hybridization probes that are currently available depend on some type of derivatization of the nucleotides to allow for detection, whether through antibody binding, or enzymatic processing, or through the fluorescence or chemiluminescence of an attached "reporter" molecule. In most cases, oligonucleotides have been derivatized to incorporate single or multiple molecules of the same reporter group, generally at specific cyclic or exocyclic positions. Techniques for attaching reporter groups have largely relied upon (a) functionalization of 5' or 3' termini of either the monomeric nucleosides or the oligonucleotide strands by numerous chemical reactions using deprotected oligonucleotides in aqueous or largely aqueous media (see Cardullo *et al.* [1988] *PNAS* 85:8790-8794); (b) synthesizing modified nucleosides containing (i) protected reactive groups, such as NH_2 , SH, CHO, or COOH, (ii) activatable monofunctional linkers, such as NHS esters, aldehydes, or hydrazides, or (iii) affinity binding groups, such as biotin, attached to either the heterocyclic base or the furanose moiety. Modifications have been made on intact oligonucleotides or to monomeric nucleosides which have subsequently been incorporated into oligonucleotides during chemical synthesis via terminal transferase or "nick translation" (see, e.g., Brumbaugh *et al.* [1988] *PNAS* 85:5610-5614; Sproat, B.S., A.I. Lamond, B. Beijer, P. Neuner, P. Ryder [1989] *Nucl Acids Res.* 17:3371-3386; Allen, D.J., P.L. Darke, S.J. Benkovic [1989] *Biochemistry* 28:4601-4607); (c) use of suitably protected

chemical moieties, which can be coupled at the 5' terminus of protected oligonucleotides during chemical synthesis, e.g., 5'-aminoethyl-3'-O-phosphoramidite (Haralambidis, J., L. Duncan, G.W. Tregar [1990] *Nucl. Acids Res.* 18:493-499); and, (d) addition of functional groups on the sugar moiety or in the phosphodiester backbone of the polymer (see Conway, N.E., J. Fidanza, L.W. McLaughlin [1989] *Nucl. Acids Res. Symposium Series* 21:43-44; Agrawal, S., P.C. Zamecnik [1990] *Nucl. Acids Res.* 18:5419-5423).

At the simplest, non-nucleoside linkers and labels have been attached to the 3' or 5' end of existing oligonucleotides by either enzymatic or chemical methods. Modification of nucleoside residues internal to the sequence of a DNA or RNA strand has proven to be a difficult procedure, since the reaction conditions must be mild enough to leave the RNA or DNA oligomers intact and still yield reaction products which can participate in normal Watson-Crick base pairing and stacking interactions (see Figure 4).

C. Derivatizations of the heterocyclic base (B). Numerous methods for both cyclic and exocyclic derivatization of the N-nucleoside base have been described, including the following:

(1) Hapten labeling. DNA probes have been amino modified and subsequently derivatized to carry a hapten such as 2,4-dinitrophenol (DNP) to which enzyme-conjugated anti-hapten antibodies bind which subsequently can be processed using a colorimetric substrate as a label (Keller *et al.* [1988] *Analytical Biochemistry* 170:441-450).

(2) Amino- and thiol-derivatized oligonucleotides. Takeda and Ikeda ([1984] *Nucl. Acids Research Symposium Series* 15:101-104) used phosphotriester derivatives of putresceinyl thymidine for the preparation of amino-derived oligomers. Ruth and colleagues have described methods for synthesizing a deoxyuridine analog with a primary amine "linker arm" 12 carbons in length at C₅ (Jablonski *et al.* [1986] *Nucl. Acids Res.* 14:6115-6128). These were later reacted with fluorescein to produce a fluorescent molecule. Urdea and Horn were granted a patent in 1990 (U.S. Patent No. 4,910,300) covering pyrimidine derivatives on which the 6-amino group at C₄ had been modified. 3' and 5' amino modifying phosphoramidites have been widely used in chemical synthesis or derivatized oligonucleotides and are commercially available.

(3) Labeling with photobiotin and other biotinylating agents. The high affinity of biotin for avidin has been used to bind enzymatic or chemiluminescent reagents to derivatized DNA probes (Foster *et al.* [1985] *Nucl. Acids Res.* 13:745-761). Biotin conjugated to other linkers has also been widely used, including biotin-NHS esters (Bayer, E.A., M. Wilchek [1980] *Methods in Biochemical Analysis* 26:1), biotin succinamides (Lee, W.T., D.H. Conrad [1984] *J. Exp. Med.* 159:1790), and biotin maleimides (Bayer, E.A. *et al.* [1985] *Anal. Biochem.* 149:529). Reisfeld *et al.* ([1987] *BBRC* 142:519-526) used biotin hydrazide to label the 4-amino group of cytidine. A patent was granted to Klevan *et al.* in 1989 (U.S. Patent No. 4,828,979) for such derivatizations at the 6-position of adenine, the 4-position of cytosine, and the 2-position of

guanine. These derivatizations interfere with hydrogen bonding and base-pairing and have limited uses in producing oligomers for use in hybridization.

(4) dU-Biotin labeling. Nucleoside 5'-triphosphates or 3'-O-phosphoramidites were modified with a biotin moiety conjugated to an aliphatic amino group at the 5-position of uracil (Langer *et al.* [1981] *PNAS* 78:6633-6637; Saiki *et al.* [1985] *Science* 230:1350-1354). The nucleotide triphosphate derivatives are effectively incorporated into double stranded DNA by standard techniques of "nick translation." Once in an oligonucleotide, the residue may be bound by avidin, streptavidin, or anti-biotin antibody which can then be used for detection by fluorescence, chemiluminescence, or enzymatic processing.

(5) 11-digoxigenin-ddUTP labeling. The enzyme, terminal transferase, has been used to add a single digoxigenin-11-dideoxyUTP to the 3' end of oligonucleotides. Following hybridization to target nucleic acids, DIG-ddUTP labeled hybridization probes were detected using anti-DIG antibody conjugate.

(6) AAIF. Immunofluorescent detection can be done using monoclonal Fab' fragments which are specific for RNA:DNA hybrids in which the probe has been derivatized with, e.g., biotin-11-UTP (Bobo *et al.* [1990] *J. Clin. Microbiol.* 28:1968-1973; Viscidi *et al.* [1986] *J. Clin. Microbiol.* 23:311-317).

(7) Bisulfite modification of cytosine. Draper and Gold ([1980] *Biochemistry* 19:1774-1781) introduced aliphatic amino groups onto cytidine by a bisulfite catalyzed termination reaction; the amino groups were subsequently labeled with a fluorescent tag. In this procedure, the amino group is attached directly to the pyrimidine base. Like the derivatization of uracil, these derivatizations interfere with hydrogen bonding and base-pairing and are not necessarily useful for producing efficient hybridization oligomers.

(8) Fluorophore derivatized DNA probes. Texas Red (Sulfochloro-Rhodamine) derivatized probes are commercially available which hybridize to specific target DNAs and which can be detected using a flow cytometer or a microscope. Numerous authors have reported coupling fluorophores to chemically synthesized oligonucleotides which carried a 5' or 3' terminal amino or thiol group (Brumbaugh *et al.* [1988] *Nucleic Acids Res.* 16:4937-4956).

(9) Direct enzyme labeling. Chemical coupling of an enzyme directly to a chemically synthesized probe has been used for direct detection through substrate processing. For example, Urdea *et al.* described an oligonucleotide sandwich assay in which multiple DNA probe hybridizations were used to bind target DNA to a solid phase after which it was further labeled with additional, alkaline phosphatase-derivatized hybridization probes (Urdea *et al.* [1989] *Clin. Chem.* 35:1571-1575).

(10) Acridinium ester labeling. A single phenyl ester of methyl acridinium is attached at a central position on an RNA or DNA probe. Hydrolysis of the ester releases an acridone, CO₂, and light. Because the ester on unhybridized probes hydrolyzes more quickly than

the ester on probes which have hybridized to target RNA or DNA, the chemiluminescence of the hybridized probes can be distinguished from that of free probes and is used in a "hybridization protection assay" (Weeks *et al.* [1983] *Clin. Chem.* 29:1474-1479).

D. Derivatizations of the furanose ring (F). Methods for derivatization of the furanose ring (R₁₁ through R₁₄ in Figure 3) and at the phosphodiester backbone of oligonucleotides (R₁₀ in Figure 3) have been reported.

(1) Internucleotide linkage reporter groups (R₁₀ site). Phosphoro-thioate esters have been used to provide a binding site for fluorophores such as monobromobimane (Conway *et al.* [1989] *Nucl. Acids Res. Symposium Series* 21:43-44). Agrawal and Zamecnik ([1990] *Nucl. Acids Res.* 18:5419-5423) reported methods for incorporating amine specific reporter groups (e.g., monobromobimane) and thiol specific reporter groups (e.g., fluorescein isothiocyanate) through modifying the phosphodiester backbone of DNA to phosphoramidites and phosphorothioate diesters, respectively.

(2) Glycosidic reporter groups (R₁₁ through R₁₄ sites). Smith, Fung, and Kaiser ([1989] U.S. Patent No. 4,849,513) described syntheses for an assortment of derivatives and labels on the glycosidic moiety of nucleosides and nucleoside analogs through the introduction of an aliphatic amino group at R₁₀. The authors did not report or claim any uses or applications of inherently fluorescent oligonucleotides, either made chemically or enzymatically or using the fluorescent nucleoside analogs or their derivatives.

E. Limitations of non-isotopic methods for labeling oligonucleotides. In order to create non-radioactive types of detectable oligonucleotides, it has been necessary to chemically modify the nucleosides typically used in DNA and RNA probes, which has made such probe preparation expensive and laborious; in many cases the detection chemistries have also proven cumbersome and expensive to use, which has largely been responsible for their failure to find significant application in clinical laboratories. In their applications to hybridization, other limitations of chemically derivatized probes have also become apparent.

(1) Chemically derivatized dNTPs are generally not cost-effective for use as stock deoxynucleotide triphosphates in PCR amplification, hence, labeling of amplified DNA is limited to (i) amplification using previously labeled primers, or (ii) annealing with labeled hybridization probes. Use of the former frequently results in false positives during amplification owing to (i) non-specific annealing of primers to non-target segments of DNA during amplification, or (ii) contamination by amplicons present in the laboratory environment which are residual from previous amplification experiments. Expense and technical difficulties in post-hybridization processing have largely limited the applications of labeled hybridization probes to research.

(2) Base pairing is hindered for many oligomers made with derivatized nucleosides through the introduction of bulky or non-hydrogen bonding bases at inappropriate

sites in a sequence. Owing to the inherent background chemiluminescence of many clinical samples, even the acridinium ester probes have failed to achieve their theoretical levels of sensitivity. The requirements for post hybridization processing have remained a limitation to such methods.

(3) It has proven difficult to provide non-radioactively labeled probes which may be inexpensively produced in large quantities.

(4) Chemiluminescent probes are short lived and samples so tested are difficult to quantify or to "reprobe" accurately.

(5) Hybridization in most cases is only inferred, is non-quantitative or only semi-quantitative, and is non-automatable.

These limitations have hindered applications of DNA and RNA hybridization probes to clinical laboratory testing and therapeutic uses.

F. Fluorescent N-nucleosides and fluorescent structural analogs. Formycin A (generally referred to as Formycin), the prototypical fluorescent nucleoside analog, was originally isolated as an antitumor antibiotic from the culture filtrates of *Nocardia interforma* (Hori *et al* [1966] *J. Antibiotics*, Ser. A 17:96-99) and its structure identified as 7-amino-3-b-D-ribofuranosyl (1H-pyrazolo-[4,3d] pyrimidine)) (Figures 5 and 6). This antibiotic, which has also been isolated from culture broths of *Streptomyces lavendulae* (Aizawa *et al* [1965] *Agr. Biol. Chem.* 29:375-376), and *Streptomyces gummaensis* (Japanese Patent No. 10,928, issued in 1967 to Nippon Kayaku Co., Ltd.), is one of numerous microbial C-ribonucleoside analogs of the N-nucleosides commonly found in RNA from all sources. The other naturally-occurring C-ribonucleosides which have been isolated from microorganisms (Figure 4) include formycin B (Koyama *et al* [1966] *Tetrahedron Lett.* 597-602; Aizawa *et al*, *supra*; Umezawa *et al* [1965] *Antibiotics* Ser. A 18:178-181), oxoformycin B (Ishizuka *et al* [1968] *J. Antibiotics* 21:1-4; Sawa *et al* [1968] *Antibiotics* 21:334-339), pseudouridine (Uematsu and Suahdolnik [1972] *Biochemistry* 11:4669-4674), showdomycin (Darnall *et al* [1967] *PNAS* 57:548-553), pyrazomycin (Sweeny *et al* [1973] *Cancer Res.* 33:2619-2623), and minimycin (Kusakabe *et al* [1972] *J. Antibiotics* 25:44-47). Formycin, formycin B, and oxoformycin B are pyrazolopyrimidine nucleosides and are structural analogs of adenosine, inosine, and hypoxanthine, respectively; a pyrazopyrimidine structural analog of guanosine obtained from natural sources has not been reported in the literature. A thorough review of the biosynthesis of these compounds is available in Ochi *et al* (1974) *J. Antibiotics* xxiv:909-916.

Physical properties of the nucleoside analogs. Because several of the C-nucleosides were known to be active as antibiotic, antiviral, or anti-tumor compounds, their chemical derivatization and physical properties have been extensively studied and compared to the structures and syntheses of the N-nucleosides commonly found in DNA and RNA. In the late 1960s, several structural analogs of the six commonly occurring N-nucleosides were found to be fluorescent under physiological conditions; fluorescence in the analogs results from a molecular rigidity of the

heterocycle structure itself; not all the structural analogs of a given type, e.g., the C-nucleosides, are fluorescent, nor is fluorescence an exclusive or inherent property of any particular class of structural analogs. Our subsequent studies have shown that only a few of the pyrazolo and pyrrolo pyrimidines and purines are fluorescent, and that the property is shared with a few other nucleoside derivatives and structural analogs including, but not limited to, several substituted N-nucleosides, azanucleosides, ethenonucleosides, and deazanucleosides, the structures of which are shown in Figures 5-11. Those structures in Figures 5-11 which are shown surrounded by boxes have been either previously reported or found to be fluorescent during development of the present invention.

Uncharacterized oligomers containing fluorescent analogs were prepared by Ward and colleagues for physical studies using then available nucleoside polymerase enzymes (Ward *et al.* [1969] *J. Biol. Chem.* 244:3243-3250; Ward *et al.* [1969] *loc cit* 1228-1237). There have been no recent reports in the literature of attempts to combine the use of fluorescent nucleosides or their structural analogs with the synthesis or hybridization techniques of molecular biology or to synthesize fluorescent oligonucleotides therefrom.

Brief Summary of the Invention

The subject invention pertains to nucleoside analogs which are fluorescent. These fluorescent nucleoside analogs are useful as monomers in synthesizing and labelling nucleotide sequences. The invention further pertains to the use of these fluorescent nucleotides which can be substituted for naturally occurring nucleosides in the synthesis of oligonucleotide probes. When used as hybridization probes, the fluorescence of such oligonucleotides can be used as a diagnostic tool to detect and identify specific genetic sequences. This methodology is distinct from other non-radioactive methods of probe detection in that it does not utilize nucleotides which have been coupled to enzymes or other reactive proteins and does not require post-hybridization processing for the detection of hybridization.

As described in the Background section, there are many shortcomings to the methods and compositions currently used in DNA and RNA probe technology. It is an object of the present invention to overcome these shortcomings of the prior art through the use of fluorescent nucleosides and their fluorescent structural analogs which can be directly incorporated into a prescribed sequence as (i) specific substitutes for a given nonfluorescent nucleotide which appear at defined locations in the complementary sequences to template or target DNA, and (ii) as labels for the identification and detection of specific sequences of template, product, amplified, or target DNA and/or RNA.

It is another object of the present invention to provide novel, inherently fluorescent nucleoside and nucleoside analogs and the novel triphosphate and phosphoramidite forms thereof, which are useful in the synthesis of labeled polynucleotide probes, amplimers, diagnostics, and

therapeutics. It is a further object of the present invention to provide methods of making autofluorescent oligonucleotides capable of specific Watson-Crick base pairing with prescribed sequences of target DNA or RNA.

5 It is another object of the invention to provide methods of using fluorescent nucleoside analogs and oligonucleotides made therefrom and synthesized according to the methods of the present invention to identify, detect the presence of, and/or alter the function of known nucleic acid sequences of DNA and RNA. Additionally, it is an object to improve and simplify the methods of detection, and to simplify the applications and uses of DNA and RNA hybridization techniques.

10 In another aspect of the invention, enzymatic methods are provided for making nucleic acid probes which are complementary to, and will bind to, only the sense or only the anti-sense, but not both, strands of a DNA duplex (asymmetric synthesis). It is an important aspect of the invention that asymmetric synthesis is the necessary condition for creating rapid and quantitative nucleic acid probe tests, assays, diagnostics, and therapeutics. A significant aspect of asymmetric
15 synthesis is its dependence on the asymmetric use of promoters, primers, or linker modified primers to direct the synthesis or isolation of oligonucleotides or oligomers using only one of the two strands of a duplex as the template. It is yet another aspect of the invention that asymmetric synthesis makes possible the directed use of multiple different templates for concurrent synthesis of a "cocktail" of asymmetric probes which can hybridize concurrently to independent and unique
20 target sites on a single piece of nucleic acid, genomic DNA, or chromosome. It is an important aspect of the invention of probe "cocktails" that if multiple copies of the same target sequence are present on a single genome, such as the multiple copies of the tandem repeat intergenic sequences disclosed in Example 3, a single asymmetric probe template can be used to create a "cocktail" which will bind to many targets on a single genome which are identical in sequence
25 but widely distributed in locus on the genome.

In one aspect of the invention, fluorescent structural analogs of the commonly occurring nucleosides and their derivatives useful in the synthesis, labeling, and detection of oligonucleotides are provided having the structural formulae of Figures 5 through 11. The commonly occurring nucleosides characteristically form hydrogen bonds in a specific donor/acceptor relationship,
30 designated Watson-Crick base pairing as shown in Figure 4. Where appropriate, specific fluorescent nucleoside analogs capable of reproducing the pattern of Watson-Crick hydrogen bond formation analogous to that of a particular commonly occurring nucleoside are provided, as indicated for, e.g., A:T and formycin:T in Figure 4 by the donor/acceptor patterns.

In another aspect of the invention, methods of making and derivatizing the fluorescent
35 structural analogs of the commonly occurring nucleosides are provided including the steps of derivatizing the R_{10} , R_{12} , and R_{14} moieties to be (i) reactive in DNA or RNA synthesis, and/or (ii) reactive in Resonance Energy Transfer of the fluorescence from the structural analogs.

In still another aspect, methods of synthesizing and using polynucleotide probes are provided using one or more of the fluorescent structural analogs and/or their derivatized forms. Such probes can be used to screen a sample containing a plurality of single stranded or double stranded polynucleotide chains and will label, detect, and identify the desired sequence, if present, by hybridization. It is an important aspect of the invention that the fluorescent oligonucleotide probes can be used with "solution hybridization" methods as depicted in Figures 12 through 18.

In accordance with the foregoing objects, the present invention comprises inherently fluorescent nucleosides which can be used to label, modify, or identify oligonucleotides made therefrom, the uses of such inherently fluorescent oligonucleotides as hybridization probes, and methods for detecting nucleotide sequences.

An important aspect of the invention is the stable fluorescence emission of the fluorophores and the use of time-resolved spectroscopy or photon counting to detect and to quantify the amount of a fluorophore present in a sample.

Additional formulae, advantages, methods of use, and novel features of the invention will be set forth in the description which follows, and in part become apparent to those skilled in the art after examination of the following, or may be learned by practice of the invention.

Brief Description of the Drawings

Figure 1 shows the six commonly-occurring N-nucleosides which predominate in DNA and RNA.

Figure 2 shows the general structures of the commonly-occurring N-nucleosides and their derivatization sites, R_n .

Figure 3 shows the general structure of the furanose ring of both the purine and pyrimidine nucleosides and the common sites, R_n for derivatization.

Figure 4 shows Watson-Crick base pairing between the normally occurring N-nucleotides A:T and G:C and base pairing between formycin:T, formycin:U, 2,6-diaminopurine:T, and 5-amino-formycin B:C.

Figure 5 shows structural analogs of the commonly-occurring N-nucleosides derived from biological sources.

Figure 6 shows the pyrazolo [4,3d] pyrimidine nucleoside analogs.

Figure 7 shows the pyrazolo [3,4d] pyrimidine nucleoside analogs.

Figure 8 shows the pyrazolo [1,5a]-1,3,5-triazine nucleoside analogs.

Figure 9 shows the azapyrimidine and azapurine nucleoside analogs.

Figure 10 shows the deazapyrimidine and deazapurine nucleoside analogs.

Figure 11 shows examples of some fluorescent structural analogs which are (I) non-H-binding, and (II) fluorescence resonance energy transfer (FRET) analogs.

Figure 12 is a diagram of symmetric RNA synthesis using FTP or ATP.

Figure 13 is a diagram of promoter directed asymmetric RNA probe synthesis using viral promoters and viral RNA polymerases.

Figure 14 is a diagram showing an example of the method for one-step labeling of ssDNA inserted at the *EcoRI* site of pUC/M13 plasmid vectors and using dF₁₀₅.

5 Figure 15 is a diagram showing the necessity of using asymmetric DNA or RNA probes for rapid and quantitative hybridization of the probe to target DNA. As shown, asymmetric probes provide significant increases in hybridization efficiencies when compared with symmetric probes.

10 Figure 16 is a diagram showing the conversion of the ribonucleotide analog, formycin A, to its 2'-deoxy triphosphate or phosphoramidite forms.

Figure 17 is a diagram of detection of a target DNA sequence in genomic DNA hybridization with fluorescent probes.

Figure 18 is a diagram of detection of an amplified DNA segment by solution hybridization of a fluorescent probe.

15 Figure 19 shows a flow chart diagramming the separation scheme used to separate reaction products from unreacted reagents following the enzymatic substitution reaction of FTP for ATP in RNA probes.

Figure 20 shows a schematic of the mechanism for increasing detection sensitivity by the use of a probe "cocktail" which contains multiple probes of different sequences.

20 Figures 21A, 21B, and 21C show specific fluorescent nucleoside analogs which have been identified and characterized as to their class, structure, chemical name, absorbance spectra, emission spectra, and methods of synthesis.

Brief Description of the Sequences

25 SEQ ID NO. 1 is a synthetic oligonucleotide according to the subject invention.

SEQ ID NO. 2 is a synthetic oligonucleotide and the complement of SEQ ID NO. 1.

SEQ ID NO. 3 is a synthetic oligonucleotide and a fluorescent analog of SEQ ID NO. 2.

Detailed Disclosure of the Invention

30 Disclosed and claimed are novel fluorescent nucleoside analogs and methods of use of the fluorescent nucleosides in, for example, nucleic acid probes and diagnostic kits. One preferred embodiment pertains to the use of inherently fluorescent nucleoside analogs in the chemical and enzymatic synthesis of DNA hybridization probes including solid phase synthesis, template directed enzymatic polymerization and amplification using polymerase chain reaction methods. Another
35 embodiment relates to the use of autofluorescent DNA hybridization probes in the identification of specific DNA sequences, e.g., gene mapping and the detection and diagnosis of infectious and genetic diseases.

Specifically, the subject invention pertains to nucleoside analogs which are fluorescent and which can be substituted for naturally occurring nucleosides in the synthesis of oligonucleotide probes. When used as hybridization probes, the fluorescence of such oligonucleotides can be used in a variety of procedures to detect and identify specific genetic sequences. This methodology is distinct from other non-radioactive methods of probe detection in that it does not utilize nucleotides which have been coupled to enzymes or other reactive proteins. Thus, described herein are applications of inherently fluorescent nucleoside analogs in developing hybridization techniques for routine, automatable clinical diagnosis.

The fluorescent analogs of the subject invention are of three general types: (A) C-nucleoside analogs; (B) N-nucleoside analogs; and (C) N-azanucleotide and N-deazanucleotide analogs. All of these compounds have three features in common: 1) they are structural analogs of the common nucleosides capable of replacing naturally occurring nucleosides in enzymatic or chemical synthesis of oligonucleotides; 2) they are naturally fluorescent when excited by light of the appropriate wavelength(s) and do not require additional chemical or enzymatic processes for their detection; and 3) they are spectrally distinct from the nucleosides commonly encountered in naturally occurring DNA. At least 125 specific compounds of the subject invention have been identified. These compounds, which have been characterized according to their class, structure, chemical name, absorbance spectra, emission spectra, and method of synthesis, are tabulated as shown in Figures 21A-21C.

Definitions. The following definitions are provided for ease in understanding the description:

"Commonly Occurring Nucleosides" are the six monomeric N-nucleotides shown in Figure 1, which predominate in naturally occurring DNA and RNA, enter into classical Watson-Crick base pairing, and are effectively non-fluorescent under physiological conditions. The respective one-letter symbols in sequence shorthand are A, C, G, T, U, and I for adenosine, cytidine, guanine, thymine, uridine, and inosine, respectively.

"Structural Analogs" of the commonly occurring nucleosides are structurally related molecules that mimic the normal purine or pyrimidine bases in that their structures (the kinds of atoms and their arrangement) are similar to the commonly occurring bases, but may have certain modifications or substitutions which do not affect basic biological activity or biochemical functions. Such base analogs include, but are not limited to, imidazole and its 2,4- and/or 5-substituted derivatives; indole and its 2-, 3-, 4-, 5-, 6-, and/or 7-substituted derivatives; benzimidazole and its 3-, 4-, and/or 5-substituted derivatives; indazole and its 3-, 4-, 5-, 6-, and/or 7-substituted derivatives; pyrazole and its 3-, 4-, and/or 5-substituted derivatives; triazole and its 4- and/or 5-substituted derivatives; tetrazole and its 5-substituted derivatives; benzotriazole and its 4-, 5-, 6-, and/or 7-substituted derivatives; 8-azaadenine and its substituted derivatives; 6-azathymine and its substituted derivatives; 6-azauracil and its substituted derivatives; 5-azacytosine

and its substituted derivatives; 8-azahypoxanthine and its substituted derivatives; pyrazolopyrimidine and its substituted derivatives; 3-deazauracil; orotic acid; 2,6-dioxo-1,2,3,6-tetrahydro-4-pyrimidine carboxylic acid; barbituric acid; uric acid; ethenoadenosine; ethenocytidine; an allopurinol (4-hydroxy-pyrazolo [3,4d] pyrimidine); or their protected derivatives as described below. Base analogs can also be any of the C-nucleosides such as are shown in Figures 4 and 5 in which the normal C-N bond between the base and the furanose ring is replaced by a C-C bond; such bases include, but are not limited to, uracil, as in the C-nucleoside pseudouridine; 1-methyluracil; 1,3-dimethyluracil; 5(4)-carbomethoxy-1,2,3-triazole; 5(4)-carboxamido-1,2,3-triazole; 3(5)-carboxymethylpyrazole; 3(5)-carbomethoxypyrazole; 5-carboethoxy-1-methylpyrazole; maleimide (in the C-nucleoside showdomycin); and 3(4)-carboxamido-4(3)-hydroxypyrazole (in the C-nucleoside pyrazomycin); and any of the other analogs listed or inferred in Figures 5 through 11; or their protected derivatives.

"Fluorophore" refers to a substance or portion thereof which is capable of emitting fluorescence in a detectable range. For the fluorescent structural analogs of the nucleotides, this fluorescence typically occurs at wavelengths in the near ultraviolet (>300 nm) through the visible wavelengths. Preferably, fluorescence will occur at wavelengths between 300 nm and 700 nm and most preferably in the visible wavelengths between 300 nm and 500 nm.

"Fluorescent Structural Analogs" are synthetic or biochemically derived monomeric structural analogs of the six commonly occurring N-nucleosides (Figure 1), such as are depicted in Figures 5 through 11, which may or may not be capable of classical Watson-Crick base pairing depending upon the monomeric structure and/or oligonucleotide in which they are used, but which are spectrally unique and distinct from the commonly occurring nucleosides in their capacities for selective excitation and emission under physiological conditions. For example, the C-nucleoside formycin A is a structural analog of adenosine that can form equivalent donor/acceptor hydrogen bonds, but which has an excitation maximum in oligonucleotides at 303 nm and an emission maximum at 405 nm (Stokes Shift = 102 nm).

"Derivatized" nucleoside analogs are fluorescent structural analogs in which reactive or protective functional groups are bound, covalently or otherwise, at the R₄ through R₉ positions of the heterocycle and/or the R₁₀(5'), the R₁₂(3'), and R₁₄(2') positions of the glycosidic moiety. Derivatives at the 2' glycosidic position may include fluorescence resonance energy transfer (FRET) acceptors or donors which enhance or accept and re-emit at longer wavelengths the inherent fluorescence emission of the fluorescent structural analog itself.

A "polynucleotide," "oligonucleotide," or "oligomer" is a nucleotide chain structure containing at least two commonly occurring nucleotides or fluorescent structural analogs. The "fluorescent oligonucleotide probe" or "fluorescent hybridization probe" provided herein is a nucleotide chain structure, as above, containing at least two monomers, at least one of which is fluorescent.

"Hybridization" is the pairwise annealing through Watson-Crick base pairing of two complementary, single-stranded molecules (see Figure 4), which may be DNA:DNA, DNA:RNA, or RNA:RNA, and in which the two strands may come from different sources. The annealing is specific (i) for complementary base pairs in which the hydrogen bond donors and acceptors are oriented as in Figure 4, and (ii) for the complementary genetic sequence of the specific gene, target DNA, or target RNA (hereinafter "target DNA/RNA") to which the probe is to be hybridized. Compare, for example, the hydrogen bond pattern of adenosine and formycin (Figure 4).

"DNA/RNA Melting Temperature" and "T_m" refer to the temperature at which the hydrogen bonds between hybridized strands of DNA or RNA are disrupted and the strands disassociate into single strands, thereby disrupting the structure of the duplex or hybrid.

"Analogous fluorescent sequence" refers to the nucleoside sequence of a polynucleotide which has been synthesized by any of the enzymatic or chemical methods described in the present invention, but in which fluorescent nucleoside analogs have been explicitly substituted for particular commonly occurring nucleosides, e.g., the substitution of formycin A-5'-triphosphate (FTP) for adenosine-5'-triphosphate (ATP), when using RNA polymerase to produce RNA probes complementary to a prescribed DNA template. In an analogous fluorescent sequence, the fluorescent nucleoside analog has been substituted in the oligonucleotide chain at some or all positions in which the corresponding commonly occurring nucleotide would have occurred in the sequence as dictated by, e.g., the template, in the case of enzymatic synthesis. Similar programmed substitutions can be made using 3'-O-phosphoramidites of the individual fluorescent analogs during standard phosphotriester synthesis. Thus, for example, the complementary sequence of the *Chlamydia tracheomatis* MOMP gene, or its fluorescent analogous sequence, can be synthesized enzymatically using dATP or dFTP, respectively, in the presence of DNA polymerase, dCTP, dTTP, and dGTP:

MOMP GENE SEQUENCE (SEQ ID NO. 1):

AAC GTT CGA GAC GGA CAC CCC TTA GGA CGA CTT GGT TCG

COMPLEMENT SEQUENCE (SEQ ID NO. 2):

TTG CAA GCT CTG CCT GTG GGG AAT CCT GCT GAA CCA AGC

ANALOGOUS FLUORESCENT SEQUENCE (SEQ ID NO. 3):

TTG CFE GCT CTG CCT GTG GGG FET CCT GCT GFF CCF FGC

wherein the fluorescent deoxyformycin A (F) residues underlined in the analogous sequence are the structural analogs of the deoxyadenosine (A) residues in the same relative positions in the complementary sequence.

"FRET acceptor" or "Fluorescence Resonance Energy Transfer acceptor" refers to a substance, substituent, chromophore, or fluorophore, e.g., a dansyl, naphthyl, anthryl, pyrenyl, methylumbelliferone, or coumarin moiety, which is capable of absorbing emitted light from fluorescent structural analog donors and re-emitting that energy at other, longer wavelengths. In

the context of the present invention, such secondary fluorophores may be selectively excited as a second label, or may be used as a fluorescence acceptor to broaden and enhance the primary fluorescence of the structural analog energy donor.

5 A. Structures, Sources, Synthesis, and Derivatization of the Fluorescent Nucleoside Analogs

Briefly, the present invention includes the heterocyclic pyrimidine or purine structural analogs of the commonly occurring nucleoside bases (B) which are fluorescent under physiological conditions and which are linked by a carbon-carbon or carbon-nitrogen bond to the set of furanose rings (designated F in Figures 4-9) of ribose ($R_{12}=R_{14}=\text{OH}$), deoxyribose ($R_{12}=\text{H}$, $R_{14}=\text{OH}$, or $R_{12}=\text{OH}$, $R_{14}=\text{H}$), or dideoxyribose ($R_{12}=R_{14}=\text{H}$) and their derivatives such as
10 are described below, and/or are apparent to one familiar with nucleotide chemistry.


For the present invention, formycin, 2-amino purine ribonucleoside, and 2,6-diamino ribonucleoside, all of which can (i) form the same or related base-pairing hydrogen bonds as adenosine, and (ii) substitute specifically for adenosine in Watson-Crick base pairing as well as
15 in a wide variety of enzymatic reactions including nucleic acid replication, ligation, and phosphorylation, are used as representatives of the set of fluorescent nucleosides and nucleoside analogs (Figure 4). Related properties and parallel claims obtain in the present invention for all other fluorescent analogs of guanosine, cytidine, thymidine, uridine, inosine, and their derivatives.

1. Structures of the nucleoside analogs. The generic purine and pyrimidine
20 structures of each type of structural analog to the commonly occurring nucleosides are given at the top of each of Figures 5 through 11, below which are representative examples of each class of analog. Only examples of the purine analogs are given in Figures 6 and 7, since the known pyrimidine analogs have already been illustrated in Figure 5. With the exception of the N-nucleoside analogs, which have only substitutions at R_4 , R_6 , and R_9 , the generic structures at the
25 top of each page show an oval encircling the part of the structure where substitutions to the heterocyclic base distinguish the analog from the commonly occurring N-nucleosides shown in Figure 1.

2. Furanose moieties common to the fluorescent nucleoside analogs. The
30 numbering of the sugar carbon atoms in furanose is 1' to 5' is indicated in Figure 2, thus the base, B, is connected to C1 of the sugar. The furanose moiety of any fluorescent heterocycle claimed in this invention has, in common with all other analogs, the set F, of glycosides and substituted glycosides, as follows: substitutions can be made, in principle, at any of the 5 sugar carbons; the subset F is defined by derivatives and/or substitutions at positions R_{10} , R_{11} , R_{12} , R_{13} , and R_{14} , which (i) are obvious to one skilled in the art, and (ii) are the furanosyl derivatives of
35 all the fluorescent nucleoside analogs claimed in the present invention. These include all phosphorous substitutions (e.g., triphosphate, thiophosphate, aminophosphate, etc.) and all protecting substitutions (e.g., dimethoxytrityl) at position R_{10} . For all glycosides, F, in Figures

5 through 11, R_{10} , R_{11} , R_{12} , R_{13} , and R_{14} are defined as follows: R_{11} and $R_{13} = H$; $R_{14} = H$, OH, or OR_i ; R_{12} and R_{10} are either H, OH, OR_m , or NHR_k , wherein (a) R_i protecting groups are typically lower aryl or alkyl ether, e.g., methyl, t-butyl, benzyl, o-nitrobenzyl, p-nitrobenzyl, o-nitrophenyl, or triphenylmethyl; or a lower alkyl or aryl ester such as acetyl, benzoyl, or p-nitrobenzoyl, or an alkyl; acetal such as tetrahydropyranyl; or a silyl ether, such as trimethylsilyl or t-butyl-dimethylsilyl; or a sulfonic acid ester such as p-toluenesulfonyl or methanesulfonyl; or halide such as bromine, fluorine, or iodine. Additional examples of suitable blocking groups may be found in Green, T.W. (1981) *Protective Groups in Organic Synthesis*, New York: Wiley & Sons. Alternatively, R_{14} may be a FRET derivative including, but not limited to, such fluorophores as 7-[3-(chlorodimethylsilyl)propoxy]-4-methylcoumarin, O-4-methylcoumarinyl-N-[3-triethoxysilyl]propylcarbamate, and N-3-triethoxysilylpropyl)dansylamide; (b) R_m represents an appropriate protecting, substituting, or reactive linker group including 2' or 3'-amido, 2' or 3'-azido, 2',3'-unsaturated, and the subset of phosphorous derivatives involved in chemical or enzymatic syntheses of oligonucleotides having a phosphate ester, thiophosphate ester, or aminophosphate ester backbone; (c) R_k is any common, standard nitrogen protecting group, such as those commonly used in peptide synthesis (Geiger, R., W. Konig [1981] In *The Peptides: Analysis, Synthesis, Biology*, Vol. 3, E. Gross, J. Meienhofer, eds., Academic Press, New York, pp. 1-99); this includes, but is not limited to, acid-labile protecting groups such as formyl, t-butyloxycarbonyl, benzyloxycarbonyl, 2-chlorobenzyloxycarbonyl, 4-chlorobenzyloxycarbonyl, 2,4-dichlorobenzyloxycarbonyl, furfuryloxycarbonyl, t-amylloxycarbonyl, adamantyloxycarbonyl, 2-phenylpropyl-(2)-oxycarbonyl, 2-(4-biphenyl)propyl-(2)-oxycarbonyl, triphenylmethyl, p-anisyldiphenylmethyl, di-p-anisyl diphenylmethyl, 2-nitrophenylsulfenyl, or diphenylphosphinyl; base labile protecting groups such as trifluoroacetyl, 9-fluorenylmethyloxycarbonyl, 4-toluene-sulfonylethyloxycarbonyl, methylsulfonylethyloxycarbonyl, and 2-cyano-t-butyloxycarbonyl; as well as others, such as chloroacetyl, acetoacetyl, 2-nitro-benzoyl, dithiasuccinoyl, maleoyl, isonicotinyl, 2-bromoethyloxycarbonyl, and 2,2,2-trichloroethyloxycarbonyl; alternatively, R_k may also be any reactive group derivatizable with a detectable label (NH_2 , SH , $=O$, and which can include an optional linking moiety including an amide, thioether or disulfide linkage, or a combination thereof with additional variable reactive groups R_1 through R_3 , such as $R_1-(CH_2)_x-R_2$, where x is an integer in the range of 1 and 8, inclusive; and R_1 , R_2 , and R_3 are H, OH, alkyl, acyl, amide, thioether, or disulfide) or any linker or spacer functioning as a homobifunctional or heterobifunctional linker including, but not limited to, such reactive groups as hydrazides, maleimidazoles, oxidizable diols, and succinimydyl groups. At most only one of R_{12} and R_{10} may be NHR_k .

The invention further includes novel phosphoramidites having the formula:



wherein B is any of the fluorescent nucleoside analogs described herein and R_{10} , R_{11} , R_{12} , R_{13} are as defined for the set of glycosides, F, as above, and R_{14} may be either H or OH. R_{16} = lower alkyl, preferably lower alkyl such as methyl or isopropyl, or heterocyclic, such as morpholino, pyrrolidono, or 2,2,6,6-tetramethylpyrrolidono; R_{15} = methyl, beta-cyanoethyl, p-nitrophenyl, o-chloronitrophenyl, or p-chlorophenyl. All other R groups are as before including those identifying spacer or linker arms of from 1 to 25 carbon atoms in length. Prior to the synthesis of the phosphoramidite at R_{12} in order to (i) preserve any reactive substituents on the heterocycle which are important to its participation in Watson-Crick base pairing, and (ii) render the amidite compatible with the DNA or RNA chain assembly chemistry, the base moiety B in the phosphoramidite can be protected, which generally involves acylation or amidation of the exocyclic amino groups and includes, but is not limited to, acetyl, benzoyl, isobutryl, succinyl, phthaloyl, or p-anisoyl; such amidine groups include, but are not limited to, dimethylformamidine, di-n-butylformamidine, or dimethylacetamidine; if B is substituted with other reactive groups such as carboxyl, hydroxyl, or mercapto, these are appropriately protected as well.

The present invention encompasses the synthesis of oligonucleotides on a solid phase support, wherein the oligomer is reacted with the protected fluorescent nucleoside analog phosphoramidites as illustrated in Figures 5 through 11 and derivatized as in the structure, above. Additionally, the present invention includes the novel fluorescent oligonucleotides having included in their sequences at least one fluorescent nucleoside analog derivatized as the phosphoramidite in the structure, above. Moreover, it is yet again another aspect of the present invention to provide fluorescent oligonucleotides made by the reactions of the aforementioned fluorescent analog 3'-O-phosphoramidites which are bound to, or have been bound by, a solid support.

3. Sources and other preparations of the fluorescent structural analogs. Formycin A is isolated as the ribonucleotide from the culture broths of *Nocardia interforma*. The antibiotic is also isolated from culture broths of *Streptomyces lavendulae* and *Streptomyces gummaensis*, and is one of numerous microbial C-ribonucleoside analogs of the N-nucleosides commonly found in RNA from all sources. The other naturally occurring C-ribonucleosides which have been isolated

from microorganisms (Figure 5) include formycin B, oxoformycin B, pseudouridine, showdownmycin, pyrazomycin, and minimycin. Formycin A, formycin B, and oxoformycin B are C-nucleosides or pyrazolopyrimidine nucleosides of the class shown in Figure 6 and are structural analogs of adenosine, inosine, and hypoxanthine, respectively; a pyrazolopyrimidine structural analog of guanosine obtained from natural sources has not been reported in the literature but can be chemically synthesized from the 2-chloro-formycin B or its deoxy form. A thorough review of the biosynthesis of these compounds is available in Ochi *et al.* (1974) *J. Antibiotics* xxiv.:909-916. Synthesis of the N₄ and N₆ derivatives of the C-nucleotides are described in Lewis and Townsend ([1980] *J. Am. Chem. Soc.* 102:2817). Corresponding syntheses for the isomeric aminopyrazolo-[3,4d]-pyrimidines are in Wierchowski *et al.* (all others are commercially available in ribose, and several in deoxy and dideoxy forms, including the azanucleotides and deaza nucleotides, or can be synthesized *de novo*, e.g., 7-deazaadenine (Gerster *et al.* [1967] *J. Med. Chem.* 10:326)). C-nucleoside analogs of the pyrazolo-s-triazine class (e.g., pyrazolo [1,5a]-1,3,5-triazine) were prepared from amino pyrazole-C-nucleoside as originally described (Fox *et al.* [1976] *J. Heterocycl. Chem.* 13:175).

Production of the deoxy, dideoxy, and phosphorylated forms of the fluorescent ribonucleoside analogs. Chemical syntheses are available in the literature for the derivatization as 2'-deoxy forms and 3'-deoxy forms of N-nucleoside, ethenonucleosides as well as the C-nucleosides (Robins *et al.* [1973] *Can. J. Chem.* 51:1313; Jain *et al.* [1973] *J. Org. Chem.* 38:3719; DeClerq *et al.* [1987] *J. Med. Chem.* 30:481). Similar procedures obtain for the deoxy forms of the azanucleotides, deazanucleotides and are found in the same and additional sources (e.g., Robins *et al.* [1977] *Can. J. Chem.* 55:1251; DeClerq *et al.*, *supra*). Protocols and procedures for synthesis of the 3'-azido, 3'-amino, 2',3'-unsaturated, and 2',3'-dideoxy analogs are as reported (Lin *et al.* [1987] *J. Med. Chem.* 30:440; Serafinowski, P. [1987] *Synthesis* 10:879). Protection or derivatization of the 2'-OH with silyl or FRET moieties can be done as by Peterson and Anderson ([1989] *Silicon Compounds: Register and Review*, Petrarch Systems, Inc., pp. 60-70).

Reported herein is the novel application of a cyclic protection procedure from the ribose to the deoxyribose conversion of C-nucleosides by which only the 2'-deoxy form of the analog is produced, and by means from which high yields can be obtained without the difficult purification necessary to separate the two isomers produced using the acetoxyisobutryl halide procedures cited above.

For enzymatic syntheses, mono- and triphosphate forms of the nucleoside analogs can be prepared by enzymatic phosphorylation with, e.g., polynucleotide kinase using established procedures, or by chemical phosphorylation. In general, the 5'-monophosphates are prepared chemically by the POCl₂ (Smith and Khorana [1958] *J. Am. Chem. Soc.* 80:1141; Yoshikawa *et al.* [1967] *Tetrahedron Lett.* 5095). The corresponding triphosphates can be chemically synthesized according to the same authors or Michelson ([1964] *Biochim. Biophys. Acta* 91:1); or Hoard and

Ott ([1965] *J. Am. Chem. Soc.* 87:1785). That is, the monophosphates are treated with carbodiimide (CDI) followed with tributylammonium pyrophosphate to give the triphosphorylated form. Where it is desired to phosphorylate analogs with exposed amino groups, such substituents can be thioacetylated by treatment with ethyl trifluorothioacetate according to the procedure of Thayer *et al.* ([1974] *Biochem. J.* 139:609).

B. Synthesis of Fluorescent Oligonucleotides

The present invention presents synthetic methods for the introduction of one or more of the fluorescent nucleoside analogs of the commonly occurring nucleotides into synthetic oligonucleotides.

1. Use of fluorescent phosphoramidites. Fluorescent phosphoramidites can be synthesized from the ribose and deoxy-ribose monomers of the fluorescent nucleoside analogs. According to the present invention, fluorescent residues are introduced into chemically synthesized oligonucleotides by first synthesizing the protected 3'-O-phosphoramidite of a nucleoside analog, e.g., 2'-deoxyformycin A; the phosphoramidite is then substituted for the corresponding standard phosphoramidite, in this case deoxy-adenosine-3'-O-phosphoramidite, and reacted with the oligonucleotide being synthesized on a solid support using standard phosphotriester chemical synthesis. The β -cyanoethyl derivatives may be selectively inserted at any desired position in a chemically synthesized oligonucleotide to produce oligomers of prescribed sequences of 60 or more bases in length and carrying any predetermined number of fluorescent bases.

For example, non-self-hybridizing oligonucleotides were synthesized which had the perfectly alternating sequences, $[AC]_x$ and $[FC]_x$, where x is the number of AC and FC dimer pairs and x had values of $x=10, 15, 20, 25, 30$, gave nearly identical values for both repetitive (>98%) and overall synthesis yields, and produced oligomers which differed only in that $[FC]_x$ was fluorescent, whereas $[AC]_x$ was not. Both oligomers hybridized specifically with complementary alternating oligomers of the sequence $[TG]_x$ but not with themselves or with noncomplementary sequences such as $[AG]_x$ and $[TC]_x$ as indicated by (i) ethidium bromide staining in agarose gels and (ii) the melting behavior of the hybrids. Equivalent values of the melt transition temperatures in 0.075 M NaCl for the $[FC]_x:[TG]_x$ and $[AC]_x:[TG]_x$ hybrids varied by less than 1°C for a given value of x (length of oligonucleotide). Specifically, one aspect of the present invention involves the synthesis of 3'-O-phosphoramidites of the fluorescent nucleotides and of their fluorescent structural analogs, the use of amidites to synthesize highly fluorescent oligonucleotides having prescribed sequences and the uses of such oligonucleotides as amplification primers, fluorescent oligonucleotide "tags," and hybridization probes.

2. Use of fluorescent polyribonucleotides and polydeoxyribonucleotides. Fluorescent polyribonucleotides and polydeoxy-ribonucleotides of prescribed sequences can be synthesized enzymatically using DNA templates from a variety of sources including those prepared by chemical

synthesis, cloning techniques, or obtained from genomic DNA. Representative syntheses of RNA oligonucleotides using three such DNA templates, *E. coli* RNA polymerase, the rNTPs cytidine, uridine, and guanosine, together with the ribose triphosphate of either formycin A or adenosine, are illustrated in Figure 12. A representative asymmetric synthesis of an RNA probe using a template bearing directional viral promoters, the viral RNA polymerases, the rNTPs cytidine, uridine, and guanosine together with the ribose triphosphate of either formycin A or adenosine, is illustrated in Figure 13. Symmetric polydeoxyribonucleotides have been made by substituting 2'-deoxyformycin A-5'-triphosphate (FTP) for deoxyadenosine-triphosphate (dATP) in standard DNA polymerase syntheses and in DNA amplifications using thermostable DNA polymerase enzymes and the polymerase chain reaction; the corresponding asymmetric syntheses have been achieved using the same reagents and procedures but with the following modifications: (i) syntheses using such DNA polymerase as Klenow fragment or modified T7 DNA polymerase employed a template into which a primer site such as the M13 forward primer sequence was incorporated into one strand of a duplex at the beginning of the sequence that was to be used as the template, and the corresponding primer was used to initiate all syntheses; (ii) primers complementary to only one strand of a template were used in amplification as is commonly described as asymmetric PCR; or (iii) paired primers in which one of each pair of primers was coupled to a linker such as biotin were used in standard DNA amplifications such as PCR, but one strand was preferentially removed by subsequent isolation such as by use of an avidinylated column or magnetic beads. Comparable syntheses can be made by other substitutions, including, e.g., the fluorescent N-nucleosides, 2-amino purine, and 2,6-amino purine (also substituted for adenosine-5'-triphosphate) and either of the fluorescent C-nucleoside triphosphates of formycin B or 5-amino-formycin B (substituted for inosine triphosphate and guanosine-triphosphate, respectively) in either their ribose and deoxyribose forms.

C. Labeling of Fluorescent Polynucleotides

RNA and DNA can be enzymatically labeled by several methods including, but not limited to, (i) 5' DNA end-labeling using both the forward phosphorylation reaction (Richardson, C.C. [1965] *PNAS* 54:158) or the exchange kinase reaction (Van de Sande *et al.* [1973] *Biochemistry* 12:5050); (ii) mixed primer labeling by extending mixed sequence hexadeoxynucleotides annealed to restriction fragments (Feinberg, A., B. Vogelstein [1983] *Anal. Biochem.* 132:6; Feinberg, A., B. Vogelstein [1984] *Anal. Biochem.* 137:266); (iii) 3' DNA end-labeling using the enzyme, terminal deoxynucleotidyl transferase, to catalyze the repetitive addition (Okayama *et al.* [1987] *Methods Enzymol.* 154:3; Heidecker, G., J. Messing [1987] *Methods Enzymol.* 154:28) of mononucleotide units of the deoxytriphosphates, or single additions of deoxytriphosphates, of several of the fluorescent nucleoside analogs to the terminal 3'-hydroxyl of DNA initiators, including nonfluorescent probes of prescribed sequence, e.g., the *Chlamydia trachomatis* MOMP

gene probe synthesized as described below; (iv) ligase labeling in which non-fluorescent "sticky-ended" or "nicked" RNA or DNA oligonucleotides are labeled by ligation with the appropriate fluorescent RNA or DNA oligomers (Pharmacia LKB [1989] *Analects* 17.2; Helfman, D.M. [1987] *Methods Enzymol.* 152:343); (v) nick translation, in which DNA polymerase is used to incorporate the triphosphates of the fluorescent analogs randomly in an existing DNA strand in a duplex (Meinkoth, J., G.M. Wahl [1987] *Methods Enzymol.* 152:91).

D. Characterization of Fluorescent Oligonucleotides of Prescribed Sequences

Hybridization, thermal melting, agarose gel characterization and fluorescence detection studies were used to characterize oligonucleotides of prescribed sequences. In some cases, the fluorescent oligonucleotides were complementary to known sequences of target DNA from clinically important pathogens or mutations, e.g., the MOMP gene sequence from *Chlamydia trachomatis*. In these studies, the templates used for enzymatic synthesis of the fluorescent oligonucleotides were the cloned fragments also intended for use later as the target DNA in subsequent hybridization studies. Hybridization of the oligonucleotides with target DNA results in quenching of the fluorescence of the structural analogs in a fluorescent probe, which fluorescence is recovered upon denaturation of the hybrid, thereby proving that hybridization has occurred. The self-hybridization of the synthetic oligonucleotide poly(rFrU), which is discussed at length, below, is representative of the results obtained in such experiments and is summarized in Table 1.

A preferred process according to the subject invention involves four basic steps. Initially the fluorescent structural analogs are chemically or biologically synthesized and, where appropriate, further derivatized as required to synthesize a fluorescent oligonucleotide probe. Second, a DNA or RNA probe molecule complementary to a nucleic acid sample of interest is constructed to have fluorescent nucleoside analogs which can be (i) distributed randomly or at specific locations throughout its length, or (ii) placed as terminal labels as described below. Third, the nucleic acid sample is then separated from unreacted monomers and can then be characterized directly, used as an extrinsic, non-specific label for tagging specific hybridization probes, or used directly as a hybridization probe. In the latter case, hybridization may take place on a solid phase to which either the target DNA/RNA or the fluorescent probe has been immobilized such as in Southern blot transfers, or "Dot-Blot" techniques, or it may occur in solution (herein, "solution hybridization"), after which probe/target hybrids are separated from unhybridized probes by simply washing or filtration. Finally, the fluorescence of the oligonucleotides hybridized to the target DNA/RNA is detected and quantified.

E. Construction of Fluorescent Probe Molecules

In accordance with the present invention, a preselected fluorescent nucleoside analog or mixture of fluorescent analogs is substituted specifically for one or more of the non-fluorescent commonly occurring nucleosides and is then incorporated into DNA or RNA oligonucleotides to create prescribed sequences. The prescribed sequences may be chosen to be equivalent in their Watson-Crick base pairing to a nucleotide sequence constructed from normally occurring nucleotides and complementary to a given target DNA or RNA sequence; such fluorescent probes are said to be analogous to the complementary sequence of the target DNA or RNA. The fluorescent probe may be synthesized by either enzymatic or chemical synthesis for subsequent applications such as (i) hybridization probes, (ii) amplimers for direct detection of amplifiable gene sequences complementary to a given set of primers, or (iii) as non-specific "universal" labels which can be attached to specific hybridization probes by, e.g., ligation.

Fluorescent nucleoside analogs of the commonly occurring ribo-, deoxy-, or dideoxyribonucleotides can be incorporated into nucleic acid polymers using one of several otherwise conventional enzymatic and chemical techniques including, but not limited to, those described here.

1. Enzymatic syntheses. Enzymatic syntheses include:

(a) the use of the enzyme DNase I to introduce small "nicks" into one strand of a double stranded DNA duplex. The holoenzyme form of *E. coli* DNA polymerase I can then be used to extend and repair these nicks using a mixture of fluorescent nucleotide analog triphosphates, e.g., deoxyformycin-5'-triphosphate (FTP), with commonly occurring deoxynucleotide triphosphates in the reaction mixture. This method introduces a large number of fluorophores randomly throughout the DNA polymer, including both strands of the double helix. In practice, the commonly occurring nucleotide, in this case dAdenosine-5'-triphosphate (dATP), can be eliminated entirely, and the dFTP substituted in its place, without significant loss of synthetic yield, loss of hybridization specificity, or strength of duplex formation as measured by the values of the DNA melting temperature;

(b) the use of a variety of enzymes, including the Klenow fragment of DNA polymerase I and the T4 DNA polymerase, to fill in overhanging single stranded regions of DNA produced by the prior actions of restriction enzymes. This method concentrates the fluorescent analogs at the end of each DNA strand. Similarly, fluorescent DNA oligonucleotides complementary to a specific DNA template can be synthesized (i) by using DNA fragments and *E. coli* DNA polymerase, or (ii) by constructing a recombinant plasmid containing the primer site for a specific primer such as the M13 forward primer immediately 5' to the desired DNA template sequence. The DNA polymerase will synthesize a complementary DNA molecule using deoxyribonucleotides or other deoxyanalogs including, e.g., dFTP as a substitute for dATP, present in the reaction mixture;

(c) an incorporation method which also produces a terminal concentration of fluorescent analogs involves the use of the "tailing" enzyme, terminal deoxynucleotide transferase, to add a homopolymer or "tail" of fluorescent deoxy analogs to the 3' end of DNA oligomers. In practice, the yields obtained in the synthesis of homopolymers when substituting fluorescent analogs for the commonly occurring nucleosides is significantly less than the yield obtained in the synthesis of heteropolymers. Alternatively, a single fluorescent nucleoside analog may be added to the 3' OH of any oligomer using the same enzyme but the dideoxy form of a fluorescent analog or a 2'-protected fluorescent analog, including the FRET protected analogs, in exactly the same manner in which, e.g., dideoxy ATP (cordecypin), is used. A third alternative method of endlabeling hybridization probes utilizes the action of DNA ligase or RNA ligase, by which non-specific double or single stranded fluorescent oligonucleotides can be covalently coupled to either the 3' or 5' end of specific hybridization probes; the fluorescent oligonucleotides used in this fashion do not necessarily participate in the Watson-Crick base pairing which determines specificity of a probe, but may act solely as a generic or universal fluorescent "tag." With each of the foregoing methods, the DNA probes are double stranded and must be denatured to single stranded form using either heat or alkali treatment prior to their use for hybridization;

(d) an incorporation method, which can also be used as a standard method of production of fluorescent probes having a prescribed length and sequence, using standard methods of DNA amplification or replication and one of several available DNA polymerases, including but not limited to the thermostable DNA polymerases, e.g., *Taq* polymerase, modified T7 DNA polymerase, Klenow fragment, and T4 DNA polymerase, but substitutes one of the fluorescent deoxyribonucleotide analogs, e.g., 2'-deoxyformycin A-5-triphosphate or 5-amino-deoxyformycin B-5'-triphosphate for ATP and GTP, respectively, in the mix of nucleotide triphosphates. The fluorescent oligonucleotides are equivalent in yield and length to the non-fluorescent oligomer made with the commonly occurring nucleotides and hybridize to target template DNA and display the same thermal stability and capacity to stain with ethidium bromide as do the nonfluorescent controls once the hybrid duplex has formed. In such amplifications, the production of fluorescent oligonucleotides can be taken directly as evidence of the presence of a particular sequence, or the identity can be further established by (i) hybridization with a defined complementary probe, and (ii) sequencing to establish the analogous sequence; and

(e) the use of fluorescent RNA oligonucleotides complementary to a specific DNA template which can be synthesized (i) symmetrically, by using DNA fragments and, e.g., *E. coli* RNA polymerase as illustrated in Figure 12, or (ii) asymmetrically, as shown in Figure 13, by constructing a recombinant plasmid containing the promoter for a specific DNA dependent RNA polymerase immediately 5' to the desired DNA sequence which is used as a template, e.g., a DNA template bearing a T7 RNA polymerase promoter immediately 5' to the fragment of a

cloned *Chlamydia* MOMP gene fragment which has the sequence which will be used as the target for hybridization with the probe. For most applications, asymmetric synthesis is the preferred method, and the corresponding DNA-dependent RNA polymerase will synthesize an RNA molecule using ribonucleotides, e.g., FTP as a substitute for ATP and UTP instead of TTP, which is the analogous complement to one, and only one, of the two strands of the template. The resulting single stranded probes can be used directly in a subsequent hybridization reaction without a denaturing step.

2. Chemical syntheses. The protected fluorescent deoxynucleoside analog-3'-O-phosphoramidites, typically those in which R_{10} = dimethoxytrityl, R_{16} = isopropyl, and R_{15} = methyl or beta-cyanoethyl, are coupled to the 5'-OH of a growing oligonucleotide attached to a solid support using standard phosphoramidite DNA synthesis techniques (see Atkinson, T., and M. Smith [1984] In *Oligonucleotide Synthesis: A Practical Approach*, M.J. Gait, ed., IRL Press, Oxford, pp. 35-82). Solid support-bound oligonucleotide, which has already been acid washed to deprotect the 5'-OH group, is reacted with 5'-trityl protected deoxynucleoside analog-3'-O-phosphoramidite in anhydrous acetonitrile in the presence of tetrazole under argon, washing away excess reagents, and then oxidizing the phosphite product to the desired phosphate with a solution of iodine in aqueous THF, and washing with anhydrous acetonitrile. After acid washing to deprotect the new 5' terminus, the cycle can be repeated as many times as necessary to achieve the desired length and sequence; additional nucleotides which are added may be the commonly occurring nucleotides or they may be additional fluorescent nucleoside analogs. Accordingly, one or more fluorophores may be incorporated within a given probe up to and including complete substitution of, e.g., all of the A residues in a desired sequence with formycin residues. The couplings can be performed manually in a minireactor vial, utilizing a 10 minute coupling time, or on a Pharmacia LKB Gene Assembler or similar instrument utilizing the programmed synthesis protocols. The fluorescent oligonucleotide is then isolated by cleaving the DNA from the porous glass support by incubation at 55°C overnight in NH_4OH :ethanol (3:1). The fluorescent DNA containing ammonium hydroxide solution can then be quickly dried in a Speed-Vac and then separated from failure sequences of a QEAE-HPLC column using a shallow salt and pH gradient. Yields for the nucleoside analog phosphoramidites are comparable to those obtained with standard amidites based on repetitive yield calculated from trityl cation release at the deprotection step.

To provide specific illustrations of how to construct and use probe molecules containing a fluorescent nucleoside analog, following are examples which illustrate procedures, including the best mode, for practicing the invention. These examples should not be construed as limiting. All percentages are by weight and all solvent mixture proportions are by volume unless otherwise noted.

Example 1 – Chemical Conversion of Formycin A to 2'-DeoxyFormycin A and Preparation of the 5'-Triphosphate and 3'-O-(2-cyanoethyl)-N,N-Diisopropyl Phosphoramidite

Figure 16 depicts the invention scheme used to make the 2'-deoxy-5'-triphosphate or 2'-deoxy-3'-O-phosphoramidite of formycin A. While the first phase has been previously accomplished by the reaction with α -acetoxisobutyryl halides as described by De Clerq *et al.* ([1987] *J. Med. Chem.* 30:481), the procedure produces both the 3' and 2' deoxy forms which are difficult to separate and are produced in low yield. The present invention employs a 3',5'-disila protection which has previously been applied successfully in the conversion of adenosine to 2'-deoxyadenosine ([1981] *J. Am. Chem. Soc.* 103:932). The method appears to be generally applicable to the corresponding conversion of many fluorescent nucleoside analogs.

(I) 7-amino-3-[3',5'-O-(1,1,3,3-tetraisopropyl-1,3-disiloxane-dilyl)- β -D-ribofuranosyl]pyrazolo [4,3d] pyrimidine. 1,3-dichloro-1,1,3,3-tetraisopropyl-1,3-disiloxane (0.9 g, 2.85 mMol) was added to a suspension of formycin A which had been exhaustively dehydrated (0.66 g, 2.5 mMol) in anhydrous pyridine and the reaction was stirred at room temperature for 24 hours. The solvent was removed under vacuum at T = 40°C and the product extracted between ethyl acetate and water. The ethyl acetate phase was washed, *in seriatim*, with (i) cold 1 N HCl, H₂O, aqueous NaHCO₃ (saturated) and aqueous NaCl (saturated) followed by evaporation to a gum. Following flash chromatography on silica gel and stepwise elution with (i) 2.5% methanol-chloroform, and (ii) 5% methanol-chloroform, the product, which ran as a single spot on silica TLC (R_f = 0.80 in 20% methanol-chloroform), was shown to be the 3',5' cyclic protected product by proton NMR and elemental analysis.

(II) 7-amino-3-[3',5'-O-(1,1,3,3-tetraisopropyl-1,3-disiloxane-dilyl)-2'-(phenoxythiocarbonyl)- β -D-ribofuranosyl]pyrazolo [4,3d] pyrimidine. 480 mg of disila protected formycin A (0.93 mMol) was dissolved with DMAP (0.9 g, 7.6 mMol) in anhydrous MeCN. Following dropwise addition of 200 mL of phenoxythiocarbonyl chloride through a dry syringe mounted in a ground glass joint, the reactants were stirred for 24 hours at room temperature, after which solvent was removed under vacuum and the product again partitioned between ethyl acetate and water. The ethyl acetate phase was washed as above, the solvent evaporated, and the residue separated on flash chromatography and eluted with chloroform-MeCN (50/50). Pooled fractions of the desired product were identified by proton NMR and elemental analysis and subjected to a second round of production, as below.

(III) 7-amino-3-(2'-deoxy- β -D-ribofuranosyl)pyrazolo [4,3d] pyrimidine (2'-deoxy formycin A). 240 mg of the product obtained from the procedure described in II, above, were added to 12.5 mg (NH₄)₂SO₄ in a gross excess of hexamethyldisilazane. The reaction mixture was refluxed at >60°C overnight. After evaporation under vacuum, the crude trisilyl derivative was redissolved in toluene and reacted with azobisisobutyronitrile and tributyl tin hydride by heating under N₂ overnight to attain complete reduction. The product was deprotected in TBAF in THF

at 80°C overnight and, after evaporation, fractionated between ethyl acetate and water. The water layer was concentrated and applied to a Dowex 50W-X8 column equilibrated in water and then eluted with 15% NH₄OH. The principal product ($R_f = 0.3$ in 20% methanol-chloroform) was shown to be identical to the purified 2'-deoxy formycin A which had been prepared using the method of De Clerq *et al.*, *supra* and by proton NMR and elemental analysis.

(IV) 7-amino-3-(2'-deoxy- β -D-ribofuranosyl) pyrazolo [4,3d] pyrimidine-5'-triphosphate (2'-deoxyformycin A-5'-triphosphate). 28 mg (0.11 mMol) of 2'-deoxyformycin A was added to a glass stoppered test tube and mixed with 0.2 mL of reagent grade acetone and 0.1 ml of phosphorous oxychloride. The heterogeneous reaction mixture was stored at 4°C for 24 hours, during which time the solution turned deep yellow. After cooling and addition of 3 ml cold acetone, 6 mMol of concentrated NH₄OH was added rapidly while mixing. After evaporation of the acetone, and reduction of the pH to less than 2, the mixture was refluxed for 1.5 hours, then diluted and applied directly to Dowex 1-formate, from which 2'-deoxyformycin A-MP was eluted with 0.75 M formic acid. 2'-deoxyformycin A-MP was converted to the triphosphate by the method of Yoshikawa *et al.* ([1967] *Tetrahedron Lett.* 5095).

(V) 7-amino-3-(2'-DEOXY- β -D-ribofuranosyl) pyrazolo [4,3d] pyrimidine-3'-O-phosphoramidite (2'-deoxyformycin A-3'-O-phosphoramidite). 2'-deoxyformycin A was treated to attain 5'-O- protection with DMT and benzylation of the 7-amino group by standard procedures. To 0.3 mMol of the product and 25 mg of diisopropylammonium tetrazolide in 1.5 mL of CH₂Cl₂ was added a solution containing 0.33 mMol of O-cyanoethyl-N,N,N',N'-tetraisopropylphosphorodiamidite. The mixture was mixed for 4 hours and partitioned between CH₂Cl₂ and chilled in saturated NaHCO₃ solution. The CH₂Cl₂ layer was washed with saturated NaCl solution, dried (Na₂SO₄), filtered, and concentrated. Purification by filtration through a 2" plug of basic alumina in a 25 mm column, eluting with 9:1 CHCl₃/ET₃N, provided the phosphoramidite which could be dried to a foam. Identity of the product was verified by proton NMR, elemental analysis, fluorescence of the heterocycle, and use in oligonucleotide synthesis.

Example 2 – Complete Enzymatic Substitution of FTP or 2'dFTP for ATP or dATP in RNA or DNA Probes

A. Symmetric synthesis of ribose oligomers. RNA oligonucleotides were synthesized from three DNA templates (Figure 10) using (i) FTP as a substitute for ATP, and (ii) a purified *E. coli* RNA polymerase as originally described by Ward *et al.* ([1969] *J. Biol. Chem.* 12:3242), except that synthesis was allowed to run for three hours at 37°C before the reaction was stopped; FTP effectively replaced ATP but not any of the other three normal nucleotides CTP, UTP, or GTP.

At the end of the synthesis, reaction products were separated from unreacted reagents by separation at 4°C on Sephadex G-50 in normal saline at pH 7. The scheme for separation of reaction products from unreacted agents is shown as a flow chart in Figure 19.

In the reaction, FTP is an effective substrate for RNA polymerase with both native and denatured DNA as well as with synthetic deoxynucleotide polymer templates. In samples containing CTP, UTP, GTP, RNA polymerase, one of the DNA templates, and either FTP or ATP, a high molecular weight product eluted from either sample in the void volume while the amount of monomeric NTP in the retained fraction from either sample was correspondingly reduced by >70%. No high molecular weight fraction other than the small amount of template eluted from enzyme-free controls and unreacted rNTPs were undiminished; similarly, template-free controls contained only unreacted rNTPs which co-eluted in the retained volume with standard ribonucleotide triphosphates. Similar results were obtained with a variety of DNA templates from natural and synthetic sources, including the alternating copolymers poly d(AC), poly (AG), and poly (ACGT). Moreover, comparable yields of high molecular weight oligomer were obtained from syntheses in which (i) the N-nucleoside analogs 2,6-diamino-adenosine-5'-triphosphate or 2-diamino-adenosine-5'-triphosphate were substituted for ATP in the reaction mix, or (ii) the C-nucleosides formycin B-5'-triphosphate (F_bTP) or -amino-formycin B-5'-triphosphate (aF_bTP) were substituted for GTP in the reaction mix and using poly (TG) or poly (GC) as the DNA template. No matter what the template, yields obtained by substituting several of the deaza- and aza-nucleoside analogs for ATP or GTP were dramatically lower.

B. Asymmetric synthesis of RNA or DNA probes. *In vitro*, DNA dependent, RNA polymerase transcription systems for the synthesis of RNAs for use as substrates and hybridization probes are a fairly common tool of molecular biology. They are uniquely applied here to the development of autofluorescent probes and their production. The method developed is general and applies to any of the phage polymerase systems, including SP6, T7, and T3. In the present case, the invention employs a pair of promoters which are separately positioned on alternate strands of a duplex plasmid and at opposite ends of a polylinker as shown in Figure 13. The vectors are used to (i) attach promoters capable of effecting asymmetric synthesis through use of a viral polymerase which recognizes one of the promoters, and (ii) replicate multiple copies of a template for use in asymmetric production of a fluorescent probe or of a nonfluorescent copy of the probe target. A copy of the DNA target sequence is inserted into the polylinker in its duplex form and at a restriction site adjacent to one of the promoters. Replication of the plasmid in competent cells provides large amounts of the template for transcription. Two separate but parallel methods have been developed for the asymmetric synthesis of DNA probes. In the first case, ssDNA probes are synthesized from templates which have primer binding site attached at the 5' end of one template strand as shown in Figure 14. In such syntheses, the primer may be non-fluorescent or may be synthesized using fluorescent analog phosphoramidites as shown at the

right of the Figure. A variation on this is asymmetric amplification and separation in which both strands of a template may be replicated by amplification as fluorescent oligomers, but using a pair of primers in which one, and only one, bears a transient affinity linker such as biotin which may subsequently be used to separate the denatured sense and antisense strands.

5 For both RNA and DNA probes, it has proven practical to establish a reference template, probe sequence, and target sequence against which all transcriptions and probe detection sensitivities are calibrated. The alpha chain of *Xenopus* translation elongation factor (Xef-1 α) serves that purpose and asymmetric RNA probe synthesis is used here as representative of all RNA and DNA synthesis. The Xef-1 α mRNA is a major transcription product of the *Xenopus* embryo which comprises a large percentage of the non-mitochondrial mRNA transcripts that appear immediately after the midblastula transition. The gene for the Xef-1 α was isolated and EcoRI linker sites added at the ends of the clone during construction of the cDNA library. The 1705 nucleotide fragment was inserted into a pSP72 plasmid bearing a T7 promoter on one strand and an SP6 promoter on the complement. Following plasmid replication and template linearization, transcription with T7 RNA polymerase, the rNTPs cytidine, uridine, and guanosine, together with the ribose triphosphate of either formycin A or adenosine, produced 1749-base-long oligomers containing 489 F or A residues, respectively. Transcripts less than full length were never observed and, in each case, the analogous and control oligomers were produced in comparable quantities and were generally indistinguishable in physical behavior save that the analogous sequence was permanently fluorescent.

15 There are two unique features of this novel manufacturing system. (1) Synthesis of the antisense strand, e.g., using SP6 and the commonly occurring nonfluorescent rNTPs provides standardized target sequences in high yield. In the corresponding asymmetric synthesis of DNA probes, distinct primer sites on complementary template strands can be used to achieve the same objective. (2) A mixture of plasmids containing several different plasmids can be used to create a "cocktail" of linearized templates from which the corresponding "cocktail" of probes (see Example 7, below), which can bind to multiple sites on a genomic sequence, can be concurrently transcribed.

30 Example 3 - The Fluorescence of Nucleoside Analog RNA Probes and Proof of Their Hybridization in Solution

35 The effective utilization of FTP in the poly d(AT) directed synthesis in Example 1 produced a polymer approximately 300-500 bases in length which, when hydrolyzed and/or sequenced, proved to be a perfectly alternating replicate of the DNA template, but with the sequence: poly (FU). As predicted from this sequence, the product could be annealed to like chains by a single thermal cycle, thereby creating the putative product poly (FU):poly (FU); unlike the comparably treated poly (FC), which showed no evidence of self-hybridization as expected, the

annealed hybrids of poly (FU):poly (FU) stained with ethidium bromide in agarose gels and gave a sharp thermal transition in both absorbance and fluorescence, proving that the probes could hybridize both effectively and specifically. The absorbance and emission spectra of the purified poly (FU), poly (FC), poly (FG), poly (UF_b), poly (CaF_b), and poly (FCGU) differ from those of purified poly (AU), poly (AC), poly (AG), poly (TG), and poly (ACGT) controls in four respects: (i) the far UV absorbance maximum is shifted slightly for the analog-containing products, to 265 nm as compared to 260 nm for the controls; (ii) there is a significant, highly structured absorbance (3 peaks at room temperature) between 290 nm and 320 nm with negligible absorbance at 340 nm; (iii) an excitation maximum appears at 303 nm; and (iv) there is a broad emission band extending into the visible wavelengths with a peak at 405 nm (Stokes shift = 102 nm). It is an important property that the fluorescence is fully quenched in, e.g., the poly (FU):poly (FU) hybrid, and cannot be detected until the strands are denatured by raising the pH of the solution to values >pH 10. Once denatured, the fluorescence of the oligomer is fully integratable, with relative fluorescence intensity >40% of peak intensity over the range 360 nm to 460 nm.

Table 1. Properties of hybrid formation by poly (AU) and poly (FU)						
RNA:RNA HYBRID	DENATURED HYBRID			INTACT HYBRID		
	WAVELENGTH MAXIMA			LENGTH (BASE PAIRS)	ETHIDIUM BROMIDE STAINING	MELT TEMP
	ABSORBANCE	EXCITATION	EMISSION			
r[AU]:r[AU]	260 nm	---	---	150-300	yes	32°C
r[FU]:r[FU]	266 nm	303 nm	405 nm	150-300	yes	33°C

Example 4 – Hybridization of Fluorescent Probes to Target RNAs and Target DNAs; Uses of Linkers to Allow Solid Phase Detection

The synthetic template poly (TG) was used to produce the complementary RNA probes poly (AC) and poly (FC), neither of which is self complementary and in which hybrids could not be annealed or detected; of the two only the poly (FC) was fluorescent. In a parallel experiment, a poly (AC) template was amplified using the biotinylated synthetic 22-mer primers, 5°BIOTIN-(TG)₁₁^{3'}, together with standard polymerase chain reaction (PCR) methods to produce the DNA amplimers having the sequence, 5°BIOTIN-poly (TG)^{3'}, then separated from the unreacted primers by gel sizing and/or QAE ion exchange chromatography, after which the polymers were radioactively labeled using ³²P-ATP and the enzyme polynucleotide kinase. When mixed separately, but in equimolar amounts, with the biotinylated amplimers, 5°BIOTIN-poly (TG)^{3'}, both of the RNA probes, poly (AC) and poly (FC), formed hybrids which could be characterized

by (i) ethidium bromide staining, and (ii) melting behavior; as expected, the fluorescence of the poly (FC) probe was quenched by hybridization. The hybrids could then be adsorbed via the ⁵BIOTIN moiety to avidinylated beads, washed to remove unhybridized poly (FC), and equal aliquots assayed for radioactivity and fluorescence. Prior to denaturation of the washed sample, detectable fluorescence in the solution was negligible; when denatured in high pH buffer, the amount of poly (FC) which had been hybridized, when estimated from the fluorescence of standardized dilutions of the probe, was within 1% of the amount of the target DNA, ⁵BIOTIN-poly (TG)³, as measured by the amount of radioactive label in the sample as compared to standardized dilutions.

Example 5 – Hybridization of Fluorescent Probes Synthesized from Nucleoside Analog-3'-O-Phosphoramidites to Target DNAs

In a validation of the use of the phosphoramidites of the fluorescent nucleoside analogs, n-mers which varied in length in multiples of 5 bases from 25-mers to 60-mers, and having the sequence (AC)_x or (FC)_x, where x = 12.5, 15, 17.5, 20, 22.5, 25, 27.5, or 30, were synthesized in parallel using either dAdenosine-3'-O-phosphoramidite or dF-3'-O-phosphoramidite together with dC-3'-O-phosphoramidite in a Pharmacia LKB Gene Assembler. After cleavage from the solid phase and purification of QAE-Sepharose, the fluorescent oligomers (FC)_x of defined length could be hybridized to the radiolabeled amplimers of poly (TG), from Examples 2 and 3, above, as assessed by DNA melting behavior, ethidium bromide staining, and the reappearance if quenched fluorescence following denaturation of the hybrid.

Example 6 – Assay for *Chlamydia trachomatis* Using an FTP Substituted RNA Probe

Chlamydia trachomatis is an obligatory intracellular pathogen which, in its active infectious stages, contains from 3x10³ to 4x10³ copies of ribosomal RNA (rRNA) and one copy of genomic DNA/bacterium. A primer pair, one of which contained a 5'-biotinylated T7 promoter which was 5' to the hybridizing primer sequence, was used to amplify a 150 base pair DNA segment of the MOMP gene from a stock strain of *C. trachomatis* L2. Approximately 500 ng of the DNA fragment, which contained the T7 RNA polymerase promoter at the 5' end, was transcribed with T7 RNA polymerase in the presence of rCTP, rUTP, rGTP, and with either rFTP or rATP (+ control). The reaction was stopped by heat inactivating the enzyme for 3 minutes at 100°C. Unincorporated rNTPs were separated from the labeled RNA by gel sizing chromatography on a Sephadex G-25 column, after which the probe concentration was estimated from its absorbance at 260 nm. Using a simple dual monochromator fluorescence spectrophotometer, as little as 5 x 10⁻¹⁴ moles of the RNA probe could be detected over background when 20 nm slits were used for both excitation and emission monochromators. A photon counting fluorimeter designed for sensitivity (see Example 9, below) is capable of detecting

between 5×10^{-16} and 5×10^{-17} moles of the same probe, equivalent to the amount of ribosomal RNA expected from between 5000 to 50,000 of the bacteria. Two hundred microliters of either (i) *C. trachomatis* genomic DNA, or (ii) the amplified target DNA were mixed with 200 μ L of a 1/200 dilution of the probe in hybridization buffer (0.15 M NaCl, 0.02 M sodium citrate, 0.02 M HEPES, 0.004 M EDTA, pH 7.4) and the mixture boiled for 3 minutes, after which they were allowed to cool slowly to room temperature over one hour. An aliquot of the genomic DNA sample was eluted into an ultrafiltration microtube or 96-well filter plate (pore size = 0.1 μ m) as illustrated in Figure 17, washed 5 times with 0.15 M NaCl, 0.02 M sodium citrate, pH 7.4, after which the sample was divided in two, one half denatured in high pH buffer, and both aliquots scanned to measure fluorescence background and the fluorescence of hybridized probe, respectively. Target DNA amplimers were treated similarly except that the 5'-biotinylated primer end of the target DNA segments were first adsorbed to avidinylated magnetic beads (2.8 μ m diameter) so that the sample could be washed without loss of material (Figure 18). With either treatment, fluorescence of the probe may be detected at dilutions of the sample which contain less than 1×10^{-16} moles of target DNA, which is roughly equivalent to the sensitivity required to detect less than 10,000 bacteria if a single similarly sized probe were used to detect rRNA from infectious *Chlamydia*. The probe used here is about 150 bases in length, contains approximately 38 formycin residues per probe, and binds only to a single target site on each copy of the ribosomal RNA. It is an important feature of this invention that increasing the number of fluorophores in a probe, or probe "cocktail," also increases the sensitivity of detection. With 13 times as many formycin residues per probe as the 150 base MOMP gene probe, 1×10^{-18} moles of the Xef-1 α probe can be detected in a dual monochromator fluorescence spectrophotometer whereas less than 1×10^{-20} moles are detected using the photon counting technology described in Example 9.

Example 7 – Detection of Multiple Target Sites

An important aspect of the asymmetric syntheses to both diagnostic and therapeutic, e.g., antisense, applications of nucleic acid probes is the capacity for concurrent synthesis of probe "cocktails" which may comprise probes which differ in length or differ in the locations or numbers of the target sites on RNA or genomic DNA to which they will bind. Utilization of probe cocktails to three different types of diagnostic targets illustrate the broad importance of this feature.

A. Single target nucleic acids present in multiple copies. In some species of pathogen, multiple copies of rRNA are present in each organism, e.g., each bacterium of *Chlamydia trachomatis* contains approximately 2×10^4 rRNA molecules per organism. Since the rRNA of *Chlamydia* is typically between 3000 and 5000 nucleotides in length, sensitivity in a diagnostic assay may be increased significantly by use of a probe cocktail specific for target sequences on

rRNA and made of as many as 5 to 10 different probe sequences, each of which can bind to discrete segments of the target rRNA or target DNA as indicated with probes (a) to (e) in the lower half of the diagram shown in Figure 20 in which (a), (b), (c), (d), and (e) are analogous complementary probes specific for different target sequences of a single DNA strand.

5 There are two disadvantages in using rRNA sequences as diagnostic targets: (i) rRNA sequences are highly conserved, hence only short variable sequences are useful for the detection and identification of infectious pathogens. One consequence of this to diagnostic sensitivity is that only limited numbers of 'reporter' labels can be used on each probe, thereby limiting sensitivity; and (ii) only a few pathogens carry rRNA in high copy numbers, and many, such as the DNA
10 viruses, carry no rRNA at all, hence the number of diagnostics which can employ this strategy is limited.

B. Multiple different target sequences on a single strand of DNA. The genomes of all organisms are significantly larger than rRNA and typically carry more numerous and larger unique segments which can serve as target sequences for nucleic acid probe hybridization. For example,
15 the complete genome of *Chlamydia trachomatis* has been isolated and consists of a relative small double stranded DNA with a molecular weight of $>660 \times 10^6$ or slightly more than 1×10^6 base pairs. Each bacterium also contains a 4.4×10^6 dalton plasmid containing >7 kbases. Unlike the rRNA of this species, the plasmid is unique to *Chlamydia* in its entirety—no cross-hybridization can be detected with the DNA from, e.g., *Neisseria gonorrhea*—indeed, no cross-hybridization
20 occurs between the different restriction fragments of the plasmid itself. Even when no other portion of the *Chlamydia* genomic DNA is chosen for use as hybridization targets, a cocktail specific for the multiple restriction fragments of the *Chlamydia* plasmid alone is equivalent in length to more than 4 Xef-1 α probes and can be detected at levels equivalent to between 100 and 1000 bacteria.

C. Multiple copies of a single target sequence on a single strand of DNA. It has only recently been discovered that flanking sequences on each side of several genes contain moderate to long stretches of tandem repeats. Ribosomal gene repeats are of particular interest in the kinds of DNA based diagnosis described in this invention. Like the ribosomal genes, they are present
25 in high copy numbers, which improves sensitivity of detection but, in addition, the spacer regions between genes are normally highly variable from species to species, since they are not subject to selective pressures. Multiple copies of the same unique sequence on a single DNA strand represents a special case in which the hybridization targets are a cocktail of loci on each genome; that is, a single probe sequence can probe multiple target sites of the same sequence and on the
30 same DNA strand. They are ideally suited as species and genus specific probe targets.

35 A representative example of such probes and targets was created for the different species of the protozoan parasite *Eimeria*, which causes coccidiosis in a variety of domestic animals. Genomic DNA from *E. tenella* was digested with several different restriction enzymes, and the

fragments ligated into appropriately cut asymmetric plasmid vectors and were used to transform *Escherichia coli*. Colonies were screened for repeat sequences by hybridization with *Eimeria tenella* genomic DNA that had been labeled with ^{35}S by random priming. Strongly hybridizing clones were picked and subjected to differential screening with labeled genomic DNA from *E. mitis*, *E.*
5 *maxima*, *E. acervulina*, and *E. tenella*, as well as DNA from the closely related genera *Plasmodium*, *Trypanosoma*, and *Sarcocystis*. The majority of clones gave signals of equal intensity with DNA from the other genera. Some clones, however, were recognized specifically by the *Eimeria* and one clone was recognized only by *E. tenella*.

The entire sequence of the insert in the latter clone contains 334 base pairs. Physical
10 characterization of the restriction fragments indicates that the sequence is present in tandemly repeated units of approximately 738 base pairs and that a minimum of 30 genes are tandemly linked and all appear to be on one chromosome. Asymmetric probes synthesized using the tandem repeat as a template contain 179 formycin A residues per template sequence.

Even when no other portion of the *Eimeria* genomic DNA is chosen for use as a
15 hybridization target, a single sequence probe specific for only the multiple copies of the tandem repeat on the *Eimeria* genome is equivalent in length to more than 11 Xef-1 α probes. Since the infectious particles for *Eimeria* are oocysts, each of which contains 8 genomes, such cocktail of targets makes it possible to detect less than 10 oocysts. The import of tandem repeat targets extends well beyond sensitivity, however, or simply the detection of this single genus, since tandem
20 repeat sequences appear in a genomic DNA of a wide variety of species and genera, and are distinct for those species, thereby providing a broad basis for the design of diagnostic assays for a wide variety of pathogens, including those for which no rRNA targets exist.

Example 8 – The Use of Non-Specific and Non-Hybridizing Fluorescent Oligomers as Universal
25 Fluorescent “Tags” by Ligation or Chemical Linkage

Simple modification of the template to produce a “sticky end” at the 3', 5', or both
3' and 5' termini, e.g., to 5'ACGT-polyd(AT), polyd(AT)-TGCA3', or 5'ACGT-polyd(AT)-
TGCA3', respectively, enabled synthesis of RNA probes with all of the above properties, but
which could also be ligated, either (i) to like strands to produce longer fluorescent probes, or (ii)
30 to other hybridization sequences specific for a prescribed target DNA. The latter is a particularly useful way in which to produce a universal label for any cloned DNA fragment, and allows a given probe to be identified by two non-hybridizing but highly fluorescent sequences at its termini, without the need to denature the hybrid for detection as was seen with the simple poly (FU) probe, above. Equivalent non-hybridizing universal probes can be readily made by chemical
35 synthesis using, e.g., the etheno analog phosphoramidites, e.g., 1,N₆-ethenoAdenosine-3'-O-phosphoramidite (eA), to synthesize non-specific tags which can subsequently be linked to any hybridization probe. In general, the 3' or 5' termini of such universal probes can also be

prepared for chemical, rather than enzymatic attachment to other oligomers or solid phases, through the addition of, e.g., 5'-amino hexyl, 5'-sulfhydryl hexyl, 3'-aminohexyl amino, N-hydroxysuccinimide esters, and other such linkers.

5 Example 9 – Quantitation of Luminescent Probe Using Time Resolved Fluorometry

10 A novel method for detecting fluorescent nucleoside analogs, fluorescent oligonucleotides or analogous sequences, of the amount of bound fluorescent oligonucleotide probe has been developed based on the use of photon counting to measure the amount of a fluorophore in a sample and is described herein below. The method differs from time resolved spectroscopy in that the method integrates all fluorescence emission from a fluorophore or nucleic acid probe, independent of the wavelength of the emission and is both a novel combination of time and spectral integration and a novel application of photon counting to the identification, detection, and quantitation of nucleic acid target sequences to diagnostic assays and therapeutic treatments.

15 The fundamental experimental parameter used in any measurement of luminescence is the intensity of the luminescence, I , the units of which are moles of photons per second per liter. Because the fluorescent nucleoside analogs used here are, for all practical purposes, permanently fluorescent and do not photobleach within the lifetime of a typical measurement, the luminescence of fluorescence, measured in moles of photons emitted per second per mole of fluorophore, can be used as an index of the amount of fluorophore, and hence probe, in a sample. The preferred instrumentation for such measurements, developed at Chromagen, comprises (i) a 150 watt Hg/Xe CW cylindrical lamp capable of high intensity excitation over the range $290 \text{ nm} \leq \lambda \leq 320 \text{ nm}$, (ii) an ultrahigh sensitivity photomultiplier in which the photodynode is coated to allow a response only over the range of emission $360 \text{ nm} \leq \lambda \leq 550 \text{ nm}$, (iii) a cylindrical cuvette with quartz excitation windows but glass walls which can serve as the emission filter. The cuvette is mounted so that the entire sample can be collected at the face of the photomultiplier tube, and (iv) 5 computer-driven photon counting clocks, connected *in seriatim*, and each capable of discriminating between photons at a frequency of 10^9 per second.

25 In experiments with the monomeric formycin A and full-length Xef-1 α probe containing 489 formycin residues under conditions of room temperature and pH = 10, we have found that (i) the luminescence of serial dilutions of the monomer and the probe are linearly related to the concentration, and (ii) the luminescence of the probe is equivalent to the same number of free monomers. In a typical assay using permanent fluorophores such as those shown in Figures 17 and 18, the amount of target present in a sample is determined by denaturing hybrids after unbound probe has been washed away and measuring the amount of probe which was bound. The fluorescence equivalence of residues in an analogous probe sequence to the emission of the same number of monomers, under alkaline conditions used here, indicates that there is negligible self-quenching in the oligomer and demonstrates that the luminescence of the probe can be used

30

35

directly to quantitate the amount of probe bound by target RNA or DNA, thereby providing a broad basis for the design of diagnostic detectors for a wide variety of nucleic acid assays and diagnostics. It is an important consequence of the invention, that sensitivity and signal-to-noise ratios are a function of the number of the photons counted and the number of time periods over which counting is done.

Example 10 – Attachment of 5' and 3' Linkers for Immobilization of the Oligonucleotides and Hybrids or for Attachment of Fluorescent Oligomers as "Labels"

The chemistries and procedures of the invention can be used to create and characterize any probe synthesized using fluorescent nucleoside analogs, whether the synthesis is enzymatic or chemical, for both fluorescence and hybridization specificity. Such probes can be used not only in the solution hybridization formats described here, but also in the more frequently used laboratory procedures such as "dot-blot" detection, electrophoresis in agarose or polyacrylamide gels, Southern blotting, and hybridization on filters and membranes, as well as separation of the hybrids by HPLC or capillary electrophoresis methods. Although linkers are not essential to the solution hybridization, any appropriate affinity linker such as biotin/avidin or homo- or heterobifunctional linker can be used to capture the probe or hybrid for purposes of concentration, isolation, or detection, as illustrated for the PCR amplified DNA fragments of Figure 13. The present invention includes linker derivatized fluorescent nucleotides, as well as oligonucleotides, linker derivatized primers for use in amplification and subsequent detection with fluorescent oligonucleotide probes, oligonucleotide probes, plasmids, and therapeutics made or otherwise "tagged" therefrom, and/or their uses and applications such as are described herein. Such derivatizations include, but are not limited to, transaminations to purine or pyrimidine nucleosides and/or their fluorescent structural analogs, amino-thiol, azido-, aldehyde, hydroxysuccinimide, 5' aminoalkyl-3'-O-phosphoramidite, 5'-thioalkyl-3'-O-phosphoramidite, 3'-aminohexyl amino, amino silanes, and aminosilyl derivatives and other such linkers and groups reactive with linkers or in condensation reactions such as Schiff base condensations of 3' or 5' oxidized *cis*-diols, as are familiar to one skilled in the art. To illustrate this a specific case is offered:

- (i) a set of non-fluorescent amplification primers for the MOMP gene sequence was chemically synthesized; at the end of synthesis an additional cycle was used to add 5'-aminohexyl-3'-O-phosphoramidite to the 5' terminus of the completed primer with the addition chemically synthesized, using standard phosphotriester chemistry.
- (ii) Following cleavage from the solid phase support in strong ethanolic base, the terminal amino group of each strand was reacted with NHS-biotin ester to provide the 5' biotinylated primers.

- (iii) The primers were used for standard amplification, after which the amplimers were captured on avidinylated 96-well filter plates and washed to remove unreacted materials and contaminants.
- (iv) The captured amplimers were hybridized with fluorescent analog labeled oligonucleotide probes as described above and the amount of target sequence in the amplimers quantified.

Included in the present invention are such attachments of fluorescent oligonucleotides to other fluorescent or non-fluorescent oligonucleotides to immobilizing beads, filters, or activated plastic plates and done through enzymatic attachment such as ligation, or chemical attachment through such linkers as are described herein.

Example 11 – Uses of Fluorescence Resonance Energy Transfer (FRET) to Broaden or Enhance the Uses of Fluorescent Nucleoside Analogs and Probes

Oligonucleotides can be synthesized or derivatized as described herein which have two or more spectrally distinct, detectable labels, either by using two or more nucleoside analogs with discrete fluorescence emission characteristics, or by use of a covalently attached FRET acceptor, such as is described hereinabove. FRET acceptors can also be used to enhance or broaden the sensitivity of the detection for the fluorescent probes, if they are simply available in solution to act as acceptors of the probe emission. For example, the excitation spectra of such dyes as the coumarins, e.g., 7-amino-4-methylcoumarin-3-acetate, 7-methyl-umbelliferone, the naphthalene and anthracene dyes, etc., overlap the emission spectrum of oligomers constructed from the fluorescent nucleoside analogs, e.g., poly (FU), but not the oligomers' excitation spectrum. Such dyes as 7-amino-4-methylcoumarin-3-acetate may thus be used either (i) as a covalently attached FRET acceptor, e.g., by reacting the N-hydroxysuccinimide ester with prescribed amino groups on the oligomer, or (ii) by simply adding the dye to a solution of the probe to act as a FRET indicator of probe fluorescence. In addition to the obvious advantages of providing a second fluorescent label to the hybridization probe, this methodology allows amplification of the probe signal through more efficient capture of the emitted light, reduction of background light due to light scattering from excitation sources, and detection at longer visible wavelengths.

It should be understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and the scope of the appended claims.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Chromagen, Inc.
- (ii) TITLE OF INVENTION: Application of Fluorescent N-Nucleosides and Fluorescent Structural Analogs of N-Nucleosides
- (iii) NUMBER OF SEQUENCES: 3
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: David R. Saliwanchik
 - (B) STREET: 2421 N.W. 41st Street, Suite A-1
 - (C) CITY: Gainesville
 - (D) STATE: FL
 - (E) COUNTRY: USA
 - (F) ZIP: 32606
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER: US
 - (B) FILING DATE:
 - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 07/834,456
 - (B) FILING DATE: 12-FEB-1992
 - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Saliwanchik, David R.
 - (B) REGISTRATION NUMBER: 31,794
 - (C) REFERENCE/DOCKET NUMBER: Chrom-1
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: 904-375-8100
 - (B) TELEFAX: 904-372-5800

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 39 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) ORIGINAL SOURCE:
 - (A) ORGANISM: Chlamydia trachomatis
 - (C) INDIVIDUAL ISOLATE: L2/434/Bu
 - (G) CELL TYPE: Bacterium
- (vi) IMMEDIATE SOURCE:
 - (A) LIBRARY: lambda 1059 recombinant
 - (B) CLONE: lambda gt11/L2/33
- (vii) POSITION IN GENOME:
 - (A) CHROMOSOME/SEGMENT: omp112 ORF
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

AACGTTTCGAG ACGGACACCC CTTAGGACGA CTTGGTTCG

39

(2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 39 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

37

- (ii) MOLECULE TYPE: transcribed DNA or RNA
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: YES
- (ix) FEATURE:
 - {A} NAME/KEY: Complementary probe
 - {C} IDENTIFICATION METHOD: Hybridization to SEQ ID NO. 1
 - {D} OTHER INFORMATION: Control for SEQ ID NO. 3
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

TTGCAAGCTC TGCCTGTGGG GAATCCTGCT GAACCAAGC

39

(2) INFORMATION FOR SEQ ID NO:3:


- (i) SEQUENCE CHARACTERISTICS:
 - {A} LENGTH: 39 base pairs
 - {B} TYPE: nucleic acid
 - {C} STRANDEDNESS: single
 - {D} TOPOLOGY: linear
- (ii) MOLECULE TYPE: transcribed DNA or RNA
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: YES
- (ix) FEATURE:
 - {A} NAME/KEY: Analogous complementary probe
 - {C} IDENTIFICATION METHOD: Hybridization to SEQ ID NO. 1
 - {D} OTHER INFORMATION: Analog to SEQ ID NO. 2
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

TTGCNNGCTC TGCCTGTGGG GNNTCCTGCT GNNCCNNGC

39

Claims

1. A fluorescent nucleoside, or structural analog thereof, having the following structure:



wherein X₁, X₂, X₃, X₄, X₅, and X₆ = N, O, C, S, or Si, wherein at least one of X₁, X₂, X₃, X₄, X₅, or X₆ = N;

R₄ is a reactive group derivatizable with a detectable label;

R₅ is H or part of an etheno linkage with R₄;

R₆ is H, NH₂, SH, or =O;

R₈ and R₉ can be hydrogen, methyl, bromine, fluorine, or iodine; alkyl or aromatic substituent, or optional linking moiety including an amide, thioether or disulfide linkage or a combination thereof such as R₁-(CH₂)_x-R₂ wherein x is an integer in from 1 to 25 inclusive, and R₁ and R₂ are H, OH, alkyl, acyl, amide, thioether, or disulfide;

R₁₀ is hydrogen, an acid-sensitive/base-stable blocking group, or a phosphorous derivative;

R₁₁ = R₁₃ = H;

R₁₂ is hydrogen, OH, 3' amino, 3'-azido, 3'-thiol, 3'-unsaturated or a 3'-phosphorous derivative; and


R₁₄ is H, OH, or OR₃ where R₃ is a reactive group, protecting group, or additional fluorophore.

2. The compound, according to claim 1, wherein R₁₀ is selected from the group consisting of H, NH₂, SH, OH, monophosphate, diphosphate, triphosphate, β,γ-methylene-2'-

triposphate, 5'-O-phosphoramidite, phosphodiester, methylphosphonate, phosphorothioate, phosphoramidite, and phosphotriester.

3. The compound, according to claim 1, wherein R_{12} is selected from the group consisting of H, OH, 3'-amino, 3'-azido, 3'-thiol, 3' unsaturated, and a 3' phosphorous derivative.

4. The compound, according to claim 1, wherein the furanose moieties are protected fluorescent nucleoside analogs having the formula:



wherein:

B is a fluorescent nucleoside analog; R_{10} is hydrogen, an acid-sensitive/base-stable blocking group, or a phosphorous derivative, $R_{11} = R_{13} = H$; and R_{14} may be either H, or OH;
 R_{15} = methyl, beta-cyanoethyl, p-nitrophenyl, o-chloronitrophenyl, or p-chlorophenyl; and
 R_{16} = lower alkyl, preferably lower alkyl such as methyl or isopropyl, or heterocyclic, such as morpholino, pyrrolidono, or 2,2,6,6-tetramethylpyrrolisone.

5. The use of a compound of claim 1 as a substitute for any of the six commonly occurring non-fluorescent N-nucleotides in the synthesis, amplification, base-pairing, labeling, sequencing, replication transcription, location, detection, or identification of DNA or RNA oligonucleotides.

6. The use, according to claim 5, wherein said amplification, synthesis, labeling, detection, or identification of DNA or RNA oligonucleotides is by (i) chemical synthesis, polymerization,

or linking methods; or (ii) enzymatic methods of amplification, replication, transcription, terminal labeling, filling in, or nick translation.

5 7. A polynucleotide probe for the detection or amplification of a target polynucleotide sequence, said probe comprising a fluorescent nucleoside.

8. The probe, according to claim 7, wherein said probe is a single stranded nucleic acid sequence of between about 5 and about 10,000 bases in length, said probe comprising a terminal fluorescent nucleotide analog or oligonucleotide comprising a fluorescent nucleotide analog bound to at least one site of said probe wherein said binding site comprises

- 10 (i) the 3' carbon, when said terminal fluorophore is at the 3' end of said probe, or
- (ii) the 5'-carbon when said terminal fluorophore is at the 5' end of said probe; or
- 15 (iii) any intermediate nucleoside residue of said probe wherein said residue which has been modified or otherwise derivatized with a reactive group, alkyl, aromatic substituent, or linking moiety; or
- (iv) a combination thereof.

9. A process for making an asymmetric single stranded fluorescent nucleic acid probe, or a symmetric, double stranded fluorescent nucleic acid probe, of known sequence, said probe comprising a compound of claim 1, wherein said probe is between about 5 and about 10,000 bases in length.

10. The process, according to claim 9, wherein said probe further comprises a 5' to 3' linker group, wherein said linker group has affinity for or chemically binds to a solid support, said support comprising glass, agarose, acrylamide, nylon, or nitrocellulose.

11. A method for detecting a target polynucleotide sequence, said method comprising contacting a sample suspected of having said target sequence with an effective amount of a composition comprising a probe of claim 7 under conditions which permit hybridization; and detecting any hybridization by observing fluorescence or changes in fluorescence.

12. The method, according to claim 11, specifically adapted for testing a sample for the presence of a biological entity or genetic mutation, associated with a target nucleic acid or specific sequence therefrom, said method comprising:

- (A) combining single stranded nucleic acid from the sample with a fluorescent nucleic acid probe of about 5 to about 10,000 bases in length, wherein said probe comprises at least one compound of claim 1,

and wherein

- (i) the sequence of the fluorescent oligonucleotide probe is analogous to the complementary sequence of the portion of the target DNA or RNA to which it is meant to hybridize;
- (ii) the fluorescent oligonucleotide probe is capable of Watson-Crick base pairing such that each fluorescent nucleoside analog forms base pairs only with the complement of the commonly occurring nucleotide for which it has been substituted; and
- (iii) the derivation of single-stranded nucleic acid with said fluorescent oligonucleotide probe is carried out under conditions that stable duplexes or hybrids form (a) only between the fluorescent oligonucleotide probes and that portion or sequence of the target DNA or RNA present in the sample to which the complementary sequence to the target DNA or RNA would bind; but (b) not significantly between fluorescent oligonucleotide probe and non-target DNA or RNA in the fragments thereof; and
- (B) determining whether stable duplex was formed in step (A) by:
- (i) (a) separating the unhybridized fluorescent oligonucleotide probe from hybridized fluorescent probe:target nucleic acid duplex formed in step (A); or (b) binding the duplexed fluorescent oligonucleotide probe, if needed, to a solid phase to facilitate washing and/or concentration;
- (ii) denaturing the isolated hybrids; and
- (iii) determining whether a detectable signal is present by the treatment of (A)(iii)(a) as an indicator of the presence of the biological entity or genetic mutation in the sample.

13. The method, according to claim 12, wherein the presence of a target nucleic acid sequence in a sample is tested by amplification using primers which have been modified at their 5' termini to enable specific chemical or affinity linkage, adsorption, or binding to a solid support, said support comprising polystyrene beads, 96 well plates, agarose, polyacrylamide, nylon, or nitrocellulose.

14. The method, according to claim 11, for detecting the presence of a target polynucleotide sequence, said method comprising:

- (A) incorporating a ribonucleotide or deoxyribonucleotide, modified by the incorporation or attachment thereto of fluorescent nucleotide analogs, into a polynucleotide complementary or analogous to the complement to said polynucleotide; and
- 5 (B) hybridizing said complementary fluorescent or analogous complementary fluorescent oligonucleotide to said target polynucleotide; and detecting the presence of said nucleotides by the fluorescence of the probe.

10 15. The method, according to claim 14, wherein said hybridizing step or detecting step is carried out on a solid phase.

16. The method, according to claim 14, wherein said target polynucleotide sequence is a disease-associated segment of the human genome.

15 17. The method, according to claim 14, wherein said target polynucleotide sequence is specific to an organism, said organism comprising a virus, viroid, bacterium, protozoan, Mollicute, trypanosome, mycobacterium, fungus, or eukaryote, where said eukaryote comprises a plant or animal.

20 18. A method for simultaneous detection of multiple sites in a genome, wherein said method comprises the use of a probe of the same or different sequence or analogous sequence, wherein said nucleic acid probe is sufficiently complementary to detectably and selectively hybridize to one or more target DNA subunit sequences of a target organism.

25 19. The method, according to claim 18, wherein said organism is a protozoan.

20. The method, according to claim 19, wherein said protozoan is Apicomplexa.

30 21. The method, according to claim 18, wherein said organism is a bacterium.

22. The method, according to claim 18, wherein said organism is a virus.

35 23. The method, according to claim 18, wherein said target polynucleotide of said organism is a single or tandem repeat of the same sequence on the same strand, but at a different locus.

24. The method, according to claim 18, wherein said target polynucleotide of said organism is a discrete segment having a different sequence, restriction fragment, and unique genomic segments, on the same DNA strand at different loci or on different DNA strands of said organism.

5

25. A method for detecting a fluorescent nucleoside analog or an oligonucleotide probe comprising a fluorescent nucleoside, said method comprising counting of photons emitted from a fluorophore per unit time and thereby determining the amount of said fluorophore in a sample.

10

26. The method, according to claim 25, wherein said photon counting method comprises integrating fluorescence emission from a fluorophore or nucleic acid probe comprising a fluorophore, wherein said fluorescence emission is independent of the maximum emission wavelength.

15

27. A kit for the determination of the presence of target nucleotide sequence in the nucleic acid of a biological sample, said kit comprising a probe of claim 7.

28. The kit, according to claim 27, wherein said kit comprises:

20

(A) a primer polynucleotide comprising a primer sequence substantially complementary to a target nucleotide sequence in a biological sample, wherein said target nucleotide sequence comprises an oligonucleotide segment complementary to the 3' terminal of said primer to form a template for primer-dependent nucleic acid polymerase;

25

(B) a plurality of nucleotide triphosphates wherein at least one of said triphosphates is a fluorescent nucleoside analog;

(C) a primer dependent DNA polymerase, wherein said polymerase extends the primers in a 5' to 3' direction when the 3' terminus of the primer is base-paired and hybridized to a template DNA sequence; and

30

(D) a fluorescent oligonucleotide probe comprising an analogous complementary sequence to said target oligonucleotide which can strongly and specifically hybridize to said target sequence for detection, identification, location, or quantification of said target nucleotide sequence.

35

29. The kit of claim 27, wherein the primer set for amplification contains or is attached to chemical or affinity linkers such as biotin for use in adsorbing, trapping, isolating, or concentrating amplified DNA or RNA sequences for use in hybridizations and detection with fluorescent analogous complementary probes.

30. A method for producing a 2'-deoxy-form of a fluorescent nucleoside analog for use in oligonucleotide synthesis, wherein said method comprises (1) conversion of said analog to a 3',5' disila protected analog, and (2) deprotection to produce the 2'-deoxy-5'-triphosphate or the 2'-deoxy-3'-*O*-phosphoramidite form of the nucleoside.

5

31. The method, according to claim 30, wherein said 2'-deoxy-nucleoside analog is converted to the 2'-deoxy-5'-triphosphate form.

10

32. The method, according to claim 30, wherein said 2'-deoxy-nucleoside analog is converted to the 2'-deoxy-3'-*O*-phosphoramidite form.




FIGURE 1




FIGURE 2




FIGURE 3




FIGURE 4




FIGURE 5








FIGURE 6




**4-AMINO-PYRAZOLO
[3,4d] PYRIMIDINE**




**4,6-DIAMINO-PYRAZOLO
[3,4d] PYRIMIDINE**




**4-AMINO-6-OXO-PYRAZOLO
[3,4d] PYRIMIDINE**




**4-OXO-PYRAZOLO
[3,4d] PYRIMIDINE**




**4-OXO-6-AMINO-PYRAZOLO
[3,4d] PYRIMIDINE**




**4,6-DIOXO-PYRAZOLO
[3,4d] PYRIMIDINE**



**PYRAZOLO
[3,4d] PYRIMIDINE**



**6-AMINO-PYRAZOLO
[3,4d] PYRIMIDINE**



**6-OXO-PYRAZOLO
[3,4d] PYRIMIDINE**

FIGURE 7






FIGURE 8



(ONLY THE PURINE ANALOGS ARE ILLUSTRATED BELOW)













FIGURE 9



(ONLY THE PURINE ANALOGS ARE ILLUSTRATED BELOW)















FIGURE 10

[I] NON-H BONDING


**1,N₆ ETHENO
PURINE NUCLEOTIDES**



**1,N₆ ETHENO
PYRIMIDINE NUCLEOTIDES**

[III] FLUORESCENCE RESONANCE ENERGY TRANSFER ANALOGS

**2'-O-(1)-NAPHTHOYL
Adenosine**



**2'-O-DIMETHYLSILYL-PROPOXY-
4-METHYL COUMARYL Adenosine**

FIGURE 11




FIGURE 12






FIGURE 13



Using a 17 mer primer, new sequence data starts at the 42nd residue
Using a 24 mer primer, new sequence data starts at the 49th residue

FIGURE 14

SYMMETRIC GENETIC PROBE HYBRIDIZATIONS



ASYMMETRIC GENETIC PROBE HYBRIDIZATIONS




FIGURE 15




FIGURE 16




FIGURE 17




FIGURE 18




FIGURE 19




FIGURE 20

1	CLASS	B GENERAL STRUCTURE	C BASE NAME	D	E	F ABSORBANCE		G ϵ ?	H EMISSION at 25°C yes/no? solvent	I pH?	J Φ	K SYNTHESIS CGN/PBO	L CODE
						abs max?	>280nm?						
2	N-Nucleoside												
3		Purines	1-methyl adenine		NO				NO				
4			2-methyl adenine		NO				NO				F45
5			3-methyl adenine		NO				NO				F47
6			6-methyl adenine		NO				NO				F48
7			6,6-Dimethyl adenine		YES				YES			CGN/PBO	F49
8			2,6-Dimethyl adenine		YES				YES				F52
9			2,2-Dimethyl adenine		YES				YES				F54
10			2-aminopurine		YES	303 nm		>9500	370 nm	H2O	7.00	CGN/PBO	F56
11			2,6-Diaminopurine		YES	304 nm		>9500	350 nm	H2O	7.00		F57
12			6-hydroxyethyl adenine										F58
13			2,8-Dihydroxy adenine										
14			8-amino adenine										
15													
16			1-methyl guanine						NO				F60
17			2-methyl guanine										F62
18			7-methyl guanine		YES				YES			CGN/PBO	F63
19			8-amino guanine		YES								F64
20			8-thio guanine		YES								F65
21			2,2-Dimethyl guanine		YES				YES				F67
22			2-methylamino guanine										
23													
24			7-methyl hypoxanthine		YES				YES			CGN/PBO	F74
25			Nebularine		YES	315 nm			YES			CGN/PBO	F77
26			2-hydroxy-6-thioguanine		YES								
27			2-thiopurine		YES	315 nm		> 20,000					
28			6-mercaptopurine		YES								
29			2-amino-6-mercaptopurine		YES	340 nm		> 20,000					
30			2-hydroxy-6-mercaptopurine		YES								
31													
32		Pyrazolo-[3,4d] pyrimidines	4-amino-pyrazolo[3,4d]pyrim.		YES	300 nm			430 nm	H2O	3.00	CGN/PBO	A13,4IPP
33			1-methyl-A13,4IPP		YES	290 nm			365 nm	H2O	3.00		F141
34			4-methyl-A13,4IPP		YES	305 nm			460 nm	H2O	7.00	CGN/PBO	F144
35			7-methyl-A13,4IPP		YES	260-320 nm			430 nm	H2O	11.00	CGN/PBO	F143
36									430 nm	H2O	3.00	CGN/PBO	
37			2-methyl-A13,4IPP		YES	300 nm			360 nm	H2O	3.00	CGN/PBO	F148
38			6-methyl-A13,4IPP		YES	260-320 nm			YES	H2O	11.00	CGN/PBO	F145
39			2,6-Dimethyl-A13,4IPP										
40			2,4-Dimethyl-A13,4IPP										
41			1,4-Dimethyl-A13,4IPP										
42			4-Mercapto-A13,4IPP										
43			4-Methylthio-A13,4IPP										
44			4-Benzylamino-A13,4IPP										
45			4,4-Dimethylamino-A13,4IPP										
46			4-Hydroxy-A13,4IPP									CGN/PBO	F147
47			4-Hydroxamino-A13,4IPP										
48			4-Methylamino-A13,4IPP									CGN/PBO	F148
49			4-Methoxy-A13,4IPP									CGN/PBO	F149
50			4-p-nitrobenzylthio-A13,4IPP										
51			4-amino-3-formidate-A13,4IPP									CGN/PBO	F150
52			4-amino-3-thiocarbamate-A13,4IPP									CGN/PBO	F151

FIGURE 21A

A	B	C	D	E	F	G	H	I	J	K	L	M
CLASS	GENERAL	BASE NAME			ABSORBANCE		EMISSION at 25°C				SYNTHESIS	CODE
	STRUCTURE			>280nm ?	abs max ?	ε ?	yes/no ?	solvent	pH ?	Φ	CGN/PBO	
53												
54												
55		4-amino-3-cyano-A[3,4]PP									CGN/PBO	
56		4-amino-3-carboxamide-A[3,4]PP									CGN/PBO	
57		4-amino-3-carboxyl-A[3,4]PP									CGN/PBO	
58		3-aminohydroxycarboxamide-4-A[3,4]PP									CGN/PBO	
59		4-amino-3-methyl-A[3,4]PP										
60												
61												
62	Pyrazolo-[2,3-d]	4-amino-pyrazolo[2,3-d]pyrim.		YES			YES	H ₂ O	7.00		CGN/PBO	A[2,3]PP
63	pyrimidines	5-methyl-A[2,3]PP		YES								
64		6-cyano-A[2,3]PP		YES								
65		6-amino-A[2,3]PP		YES								
66		6-cyano-A[2,3]PP		YES								
67		8-amino-A[2,3]PP		YES								
68		6-carbamoyl-A[2,3]PP		YES								
69		6-carbamoyl-A[2,3]PP		YES								
70		6-methyl-A[2,3]PP		YES								
71		7-deazaguanine		YES			YES	H ₂ O	7.00		CGN/PBO	
72												
73												
74	Azanucleotides	8-azaadenine					YES					
75		8-aza-2,8-Diaminopurine										
76		2-amino-8-azaguanine										
77		8-azaguanine					YES					
78		8-azahypoxanthine										
79												
80												
81	Deaza-	3-Deazaadenine										
82	nucleotides	8-amino-3-deazaadenine										
83		8-methyl-3-deazaadenine										
84		7-Deazanebularine					400 nm	H ₂ O	7.00			
85												
86	C-Nucleoside											
87	Pyrazolo-[4,3-d]	7-amino-		YES	283 nm		348 nm	H ₂ O	7.00	0.06		F105
88	pyrimidines				303 nm		405 nm	H ₂ O	11.00	0.07		
89					303 nm		405 nm	EtOH	11.00	0.12		
90					303 nm		405 nm	PropGlycol	11.00	0.23		
91					303 nm		405 nm	DMF	11.00	0.24		
92												
93		1-methyl-F105		YES	>300 nm		355 nm	H ₂ O	11.00	0.09	CGN/PBO	F164
94		2-methyl-F105		YES	>300 nm		360 nm	H ₂ O	11.00	0.085	CGN/PBO	F165
95		4-methyl-F105		YES	>300 nm		445 nm	H ₂ O	11.00	0.09 - 0.1	CGN/PBO	F172
96		5-amino-Pyrazolo-[4,3-d] pyrim		YES	>300 nm		YES	H ₂ O	11.00	0.6		F142
97		2,6-anthridio-F105		YES	>300 nm		YES	H ₂ O	11.00			
98		7-methyl-F105		YES	>300 nm		YES	H ₂ O	11.00			
99		6-methyl-F105		YES	>300 nm		YES	H ₂ O	11.00		CGN/PBO	F125
100		4,2-Dimethyl-F105		YES	>300 nm		440 nm	H ₂ O	11.00	0.002	CGN/PBO	F120
101		7-methylamino-2-methyl-F105		YES	>300 nm		YES	H ₂ O	11.00		CGN/PBO	
102				YES	>300 nm		YES	H ₂ O	11.00			
103		7-keto-		YES	>300 nm		348 nm	H ₂ O	7.00		CGN/PBO	F132
104				YES	>300 nm		410 nm	H ₂ O	11.00		CGN/PBO	

FIGURE 21B

A	B	C	D	E	F	G	H	I	J	K	L	M
CLASS	GENERAL STRUCTURE	BASE NAME		>280nm ?	ABSORBANCE abs max ?	ε ?	EMISSION at 25°C yes/no ?	solvent	pH ?	Φ	SYNTHESIS	CODE
105												
106												
107					>300 nm		410 nm	EtOH	11.00		CGN /PBO	
108					>300 nm		410 nm	PropGlycol	11.00		CGN /PBO	
109					>300 nm		410 nm	DMF	11.00		CGN /PBO	
110		1-methyl-F132		YES							CGN	F133
111		2-methyl-F132		YES							CGN	F134
112		4-methyl-F132		YES							CGN	F135
113		6-methyl-F132		YES							CGN	F136
114		7-methyl-F132		YES							CGN	F137
115		7-thio-F132									CGN	
116		7-methyl-1-ethyl-pyrazolo[4,3-d]pyrim.									CGN	
117		7-Dimethyl-1-ethyl-pyrazolo[4,3-d]pyrim.									CGN	
118		4,2-Dimethoxy-pyrazolo[4,3-d]pyrim									CGN	
119		Oxoformycin B		YES							CGN	
120		1-methyl-Oxoformycin B		YES							/PBO	
121		2-methyl-Oxoformycin B		YES							/PBO	
122											/PBO	
123	Pyrazolo-[1,5-a]											
124	1,3,5-triazines	4-aminopyrazolo[1,5-a]triazine		YES							/PBO	APTR
125		4-ThioAPTR		YES							/PBO	
126		4-methylthioAPTR		YES							/PBO	
127		4-Hydroxy-APTR		YES							/PBO	
128		4-Oxo-3H-PTR		YES							/PBO	OPTR
129												
130												
131												
132												
133												
134												
135												
136												
137												
138												

Syntheses: CGN = Synthesis done or synthesis in process at Chromagen; PBO = synthesis done by or synthesis in process at other laboratory
Φ = values are relative to quinine sulfate in 0.117 N HClO4 and are ± 10%

FIGURE 21C